<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35538578</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-7819</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>World journal of surgical oncology</Title>
          <ISOAbbreviation>World J Surg Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.</ArticleTitle>
        <Pagination>
          <StartPage>146</StartPage>
          <MedlinePgn>146</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">146</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12957-022-02602-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Glioblastoma is one of the most aggressive tumors. The etiology and the factors determining its onset are not yet entirely known. This study investigates the origins of GBM, and for this purpose, it focuses primarily on developmental gliogenic processes. It also focuses on the impact of the related neurogenic developmental processes in glioblastoma oncogenesis. It also addresses why glial cells are at more risk of tumor development compared to neurons.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Databases including PubMed, MEDLINE, and Google Scholar were searched for published articles without any date restrictions, involving glioblastoma, gliogenesis, neurogenesis, stemness, neural stem cells, gliogenic signaling and pathways, neurogenic signaling and pathways, and astrocytogenic genes.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The origin of GBM is dependent on dysregulation in multiple genes and pathways that accumulatively converge the cells towards oncogenesis. There are multiple layers of steps in glioblastoma oncogenesis including the failure of cell fate-specific genes to keep the cells differentiated in their specific cell types such as p300, BMP, HOPX, and NRSF/REST. There are genes and signaling pathways that are involved in differentiation and also contribute to GBM such as FGFR3, JAK-STAT, and hey1. The genes that contribute to differentiation processes but also contribute to stemness in GBM include notch, Sox9, Sox4, c-myc gene overrides p300, and then GFAP, leading to upregulation of nestin, SHH, NF-κB, and others. GBM mutations pathologically impact the cell circuitry such as the interaction between Sox2 and JAK-STAT pathway, resulting in GBM development and progression.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Glioblastoma originates when the gene expression of key gliogenic genes and signaling pathways become dysregulated. This study identifies key gliogenic genes having the ability to control oncogenesis in glioblastoma cells, including p300, BMP, PAX6, HOPX, NRSF/REST, LIF, and TGF beta. It also identifies key neurogenic genes having the ability to control oncogenesis including PAX6, neurogenins including Ngn1, NeuroD1, NeuroD4, Numb, NKX6-1 Ebf, Myt1, and ASCL1. This study also postulates how aging contributes to the onset of glioblastoma by dysregulating the gene expression of NF-κB, REST/NRSF, ERK, AKT, EGFR, and others.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shafi</LastName>
            <ForeName>Ovais</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-0572-6129</Identifier>
            <AffiliationInfo>
              <Affiliation>Sindh Medical College - Jinnah Sindh Medical University / Dow University of Health Sciences, Karachi, Pakistan. dr.ovaisshafi@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Ghazia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Sindh Medical College - Jinnah Sindh Medical University / Dow University of Health Sciences, Karachi, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>World J Surg Oncol</MedlineTA>
        <NlmUniqueID>101170544</NlmUniqueID>
        <ISSNLinking>1477-7819</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C083431">SOX4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055751">SOXC Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055751" MajorTopicYN="N">SOXC Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aging</Keyword>
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma origins</Keyword>
        <Keyword MajorTopicYN="N">Gliogenesis</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Neurogenesis</Keyword>
        <Keyword MajorTopicYN="N">Oncogenesis</Keyword>
        <Keyword MajorTopicYN="N">Regeneration</Keyword>
        <Keyword MajorTopicYN="N">Stem cells</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>23</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35538578</ArticleId>
        <ArticleId IdType="pmc">PMC9087910</ArticleId>
        <ArticleId IdType="doi">10.1186/s12957-022-02602-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12957-022-02602-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–397. doi: 10.1016/B978-0-12-802997-8.00023-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-802997-8.00023-2</ArticleId>
            <ArticleId IdType="pubmed">26948367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme - an overview. Contemp Oncol (Pozn). 2014;18(5):307–312. doi: 10.5114/wo.2014.40559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2014.40559</ArticleId>
            <ArticleId IdType="pmc">PMC4248049</ArticleId>
            <ArticleId IdType="pubmed">25477751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48–56. doi: 10.3109/07357907.2011.630050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07357907.2011.630050</ArticleId>
            <ArticleId IdType="pmc">PMC3799884</ArticleId>
            <ArticleId IdType="pubmed">22236189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafi O. Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review. BMC Neurol. 2016;16:236. doi: 10.1186/s12883-016-0765-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-016-0765-2</ArticleId>
            <ArticleId IdType="pmc">PMC5120447</ArticleId>
            <ArticleId IdType="pubmed">27875990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–S8. doi: 10.1188/16.CJON.S1.2-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1188/16.CJON.S1.2-8</ArticleId>
            <ArticleId IdType="pmc">PMC5123811</ArticleId>
            <ArticleId IdType="pubmed">27668386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807–821. doi: 10.1038/nrc1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1208</ArticleId>
            <ArticleId IdType="pubmed">14557817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Liu Z, Balivada S, et al.  Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther. 2012;3:5. doi: 10.1186/scrt96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/scrt96</ArticleId>
            <ArticleId IdType="pmc">PMC3340549</ArticleId>
            <ArticleId IdType="pubmed">22330721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira-Nunes MC, Assad Kahn S, de Oliveira Barbeitas AL, et al.  The availability of the embryonic TGF-β protein Nodal is dynamically regulated during glioblastoma multiforme tumorigenesis. Cancer Cell Int. 2016;16:46. doi: 10.1186/s12935-016-0324-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-016-0324-3</ArticleId>
            <ArticleId IdType="pmc">PMC4912793</ArticleId>
            <ArticleId IdType="pubmed">27330409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Pan JQ, Luo L, et al.  NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi: 10.1186/1476-4598-14-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-14-2</ArticleId>
            <ArticleId IdType="pmc">PMC4429406</ArticleId>
            <ArticleId IdType="pubmed">25971746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi: 10.1056/NEJMra0708126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0708126</ArticleId>
            <ArticleId IdType="pubmed">18669428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev. 2006;17(1-2):29–40. doi: 10.1016/j.cytogfr.2005.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2005.09.006</ArticleId>
            <ArticleId IdType="pubmed">16289860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Son MJ, Woolard K, et al.  Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell. 2008;13(1):69–80. doi: 10.1016/j.ccr.2007.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2007.12.005</ArticleId>
            <ArticleId IdType="pmc">PMC2835498</ArticleId>
            <ArticleId IdType="pubmed">18167341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi G, Best B, Mania-Farnell B, James CD, Tomita T. Therapeutic potential for bone morphogenetic protein 4 in human malignant glioma. Neoplasia. 2017;19(4):261–270. doi: 10.1016/j.neo.2017.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC5342987</ArticleId>
            <ArticleId IdType="pubmed">28278424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sachdeva R, Wu M, Johnson K, Kim H, Celebre A, Shahzad U, Graham MS, Kessler JA, Chuang JH, Karamchandani J, Bredel M, Verhaak R, Das S. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Sci Rep. 2019;9(1):14569. doi: 10.1038/s41598-019-51270-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-51270-1</ArticleId>
            <ArticleId IdType="pmc">PMC6787003</ArticleId>
            <ArticleId IdType="pubmed">31602000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampazzo E, Dettin M, Maule F, Scabello A, Calvanese L, D'Auria G, Falcigno L, Porcù E, Zamuner A, Della Puppa A, Boso D, Basso G, Persano L. A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation. Biochim Biophys Acta Gen Subj. 2017;1861(9):2282–2292. doi: 10.1016/j.bbagen.2017.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2017.07.001</ArticleId>
            <ArticleId IdType="pubmed">28687190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-β signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4449428</ArticleId>
            <ArticleId IdType="pubmed">26045979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, Kim H. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22):7125–7134. doi: 10.1158/0008-5472.CAN-11-1330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1330</ArticleId>
            <ArticleId IdType="pubmed">21975932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-García A, Samsó P, Fontova P, Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U, Ventura F, Navarro-Sabaté À, Bartrons R. TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. FEBS J. 2017;284(20):3437–3454. doi: 10.1111/febs.14201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.14201</ArticleId>
            <ArticleId IdType="pubmed">28834297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegge B, Sjøttem E, Mikkola I. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress. BMC Cancer. 2018;18:496. doi: 10.1186/s12885-018-4394-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4394-6</ArticleId>
            <ArticleId IdType="pmc">PMC5930953</ArticleId>
            <ArticleId IdType="pubmed">29716531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol. 2005;71(3):223–229. doi: 10.1007/s11060-004-1720-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-004-1720-4</ArticleId>
            <ArticleId IdType="pubmed">15735909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molofsky AV, Krencik R, Ullian EM, et al.  Astrocytes and disease: a neurodevelopmental perspective [published correction appears in Genes Dev. 2012 Jul 1;26(13):1508. Krenick, Robert [corrected to Krencik, Robert]; Ullian, Erik [corrected to Ullian, Erik M]] Genes Dev. 2012;26(9):891–907. doi: 10.1101/gad.188326.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.188326.112</ArticleId>
            <ArticleId IdType="pmc">PMC3347787</ArticleId>
            <ArticleId IdType="pubmed">22549954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F, Yung WK, Zhou YH. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res. 2006;66(20):9809–9817. doi: 10.1158/0008-5472.CAN-05-3877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3877</ArticleId>
            <ArticleId IdType="pubmed">17047041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou YH, Hu Y, Mayes D, et al.  PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. J Neurooncol. 2010;96:191–200. doi: 10.1007/s11060-009-9963-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-009-9963-8</ArticleId>
            <ArticleId IdType="pmc">PMC2808537</ArticleId>
            <ArticleId IdType="pubmed">19618119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gómez-López S, Wiskow O, Favaro R, Nicolis SK, Price DJ, Pollard SM, Smith A. Sox2 and Pax6 maintain the proliferative and developmental potential of gliogenic neural stem cells In vitro. Glia. 2011;59(11):1588–1599. doi: 10.1002/glia.21201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.21201</ArticleId>
            <ArticleId IdType="pubmed">21766338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson TI, Price DJ. Pax6; a pleiotropic player in development. Bioessays. 2002;24(11):1041–1051. doi: 10.1002/bies.10174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bies.10174</ArticleId>
            <ArticleId IdType="pubmed">12386935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakurela S, Tiwari N, Schick S, et al.  Mapping gene regulatory circuitry of Pax6 during neurogenesis. Cell Discov. 2016;2:15045. doi: 10.1038/celldisc.2015.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/celldisc.2015.45</ArticleId>
            <ArticleId IdType="pmc">PMC4860964</ArticleId>
            <ArticleId IdType="pubmed">27462442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panicker SP, Raychaudhuri B, Sharma P, et al.  p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget. 2010;1(4):289–303. doi: 10.18632/oncotarget.100801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.100801</ArticleId>
            <ArticleId IdType="pmc">PMC3248108</ArticleId>
            <ArticleId IdType="pubmed">21304179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagalwala MN, Singh SK, Majumder S. Stemness is only a state of the cell. Cold Spring Harb Symp Quant Biol. 2008;73:227–234. doi: 10.1101/sqb.2008.73.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/sqb.2008.73.042</ArticleId>
            <ArticleId IdType="pubmed">19150961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu T, Aron L, Zullo J, et al.  REST and stress resistance in ageing and Alzheimer’s disease. Nature. 2014;507(7493):448–454. doi: 10.1038/nature13163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13163</ArticleId>
            <ArticleId IdType="pmc">PMC4110979</ArticleId>
            <ArticleId IdType="pubmed">24670762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamal MM, Sathyan P, Singh SK, Zinn PO, Marisetty AL, Liang S, Gumin J, El-Mesallamy HO, Suki D, Colman H, Fuller GN, Lang FF, Majumder S. REST regulates oncogenic properties of glioblastoma stem cells. Stem Cells. 2012;30(3):405–414. doi: 10.1002/stem.1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1020</ArticleId>
            <ArticleId IdType="pmc">PMC4039365</ArticleId>
            <ArticleId IdType="pubmed">22228704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Li Y, Wang R, Li Y, Shi P, Kan Z, Pang X. Inhibition of REST suppresses proliferation and migration in glioblastoma cells. Int J Mol Sci. 2016;17(5):664. doi: 10.3390/ijms17050664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17050664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marisetty AL, Lu L, Veo BL, et al.  REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Neuro Oncol. 2019;21(6):775–785. doi: 10.1093/neuonc/noz030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz030</ArticleId>
            <ArticleId IdType="pmc">PMC6556851</ArticleId>
            <ArticleId IdType="pubmed">30953587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang JY, Zukin RS. REST, a master transcriptional regulator in neurodegenerative disease. Curr Opin Neurobiol. 2018;48:193–200. doi: 10.1016/j.conb.2017.12.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.conb.2017.12.008</ArticleId>
            <ArticleId IdType="pmc">PMC5892838</ArticleId>
            <ArticleId IdType="pubmed">29351877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson R, Chan C. NRSF and its epigenetic effectors: new treatments for neurological disease. Brain Sci. 2018;8(12):–226. Published 2018 Dec 19. 10.3390/brainsci8120226.</Citation>
        </Reference>
        <Reference>
          <Citation>Halfter H, Kremerskothen J, Weber J, Hacker-Klom U, Barnekow A, Ringelstein EB, Stögbauer F. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. J Neurooncol. 1998;39(1):1–18. doi: 10.1023/a:1005901423332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1005901423332</ArticleId>
            <ArticleId IdType="pubmed">9760066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ardizzone A, Scuderi SA, Giuffrida D, Colarossi C, Puglisi C, Campolo M, Cuzzocrea S, Esposito E, Paterniti I. Role of fibroblast growth factors receptors (FGFRs) in brain tumors, focus on astrocytoma and glioblastoma. Cancers (Basel). 2020;12(12):3825. doi: 10.3390/cancers12123825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12123825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loilome W, Joshi AD, Rhys a CM, Piccirillo S, Vescovi AL, Gallia GL, Riggins GJ. Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol. 2009;94(3):359–366. doi: 10.1007/s11060-009-9885-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-009-9885-5</ArticleId>
            <ArticleId IdType="pubmed">19340397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jimenez-Pascual A, Siebzehnrubl FA. Fibroblast growth factor receptor functions in glioblastoma. Cells. 2019;8(7):715. doi: 10.3390/cells8070715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8070715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez AM, Berry M, Maher PA, Logan A, Baird A. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain Res. 1995;701(1-2):201–226. doi: 10.1016/0006-8993(95)01002-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(95)01002-x</ArticleId>
            <ArticleId IdType="pubmed">8925285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake A, Hattori Y, Ohta M, Itoh N. Rat oligodendrocytes and astrocytes preferentially express fibroblast growth factor receptor-2 and -3 mRNAs. J Neurosci Res. 1996;45(5):534–41. 10.1002/(SICI)1097-4547(19960901)45:5&lt;_x0035_34:_x003a_AIDJNR3&gt;3.0.CO;2-D.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohashi R, Matsuda Y, Ishiwata T, Naito Z. Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma. Oncol Rep. 2014;32(3):1163–1169. doi: 10.3892/or.2014.3283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2014.3283</ArticleId>
            <ArticleId IdType="pubmed">24968791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliva CR, Halloran B, Hjelmeland AB, et al.  IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell Commun Signal. 2018;16:61. doi: 10.1186/s12964-018-0273-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-018-0273-7</ArticleId>
            <ArticleId IdType="pmc">PMC6148802</ArticleId>
            <ArticleId IdType="pubmed">30231881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Carro MS, Curiel-García A, Campos C, Pourmaleki M, Grommes C, Vivanco I, Rohle D, Bielski CM, Taylor BS, Hollmann TJ, Rosenblum M, Tempst P, Blenis J, Squatrito M, Mellinghoff IK. EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nat Commun. 2017;8(1):2035. doi: 10.1038/s41467-017-02185-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02185-w</ArticleId>
            <ArticleId IdType="pmc">PMC5725448</ArticleId>
            <ArticleId IdType="pubmed">29229958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462–1466. doi: 10.1158/1078-0432.CCR-04-1737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1737</ArticleId>
            <ArticleId IdType="pubmed">15746047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ou A, Ott M, Fang D, Heimberger AB. The role and therapeutic targeting of JAK/STAT signaling in glioblastoma. Cancers (Basel). 2021;13(3):437. doi: 10.3390/cancers13030437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13030437</ArticleId>
            <ArticleId IdType="pmc">PMC7865703</ArticleId>
            <ArticleId IdType="pubmed">33498872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puram SV, Yeung CM, Jahani-Asl A, Lin C, de la Iglesia N, Konopka G, Jackson-Grusby L, Bonni A. STAT3-iNOS signaling mediates EGFRvIII-induced glial proliferation and transformation. J Neurosci. 2012;32(23):7806–7818. doi: 10.1523/JNEUROSCI.3243-11.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3243-11.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3409246</ArticleId>
            <ArticleId IdType="pubmed">22674257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE., Jr Stat3 as an oncogene. Cell. 1999;98(3):295–303. doi: 10.1016/s0092-8674(00)81959-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0092-8674(00)81959-5</ArticleId>
            <ArticleId IdType="pubmed">10458605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14(19):6042–6054. doi: 10.1158/1078-0432.CCR-07-4923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-4923</ArticleId>
            <ArticleId IdType="pmc">PMC2707832</ArticleId>
            <ArticleId IdType="pubmed">18829483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003;63(14):3923–3930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12873986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JE, Patel M, Ruzevick J, Jackson CM, Lim M. STAT3 activation in glioblastoma: biochemical and therapeutic implications. Cancers (Basel). 2014;6(1):376–395. doi: 10.3390/cancers6010376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6010376</ArticleId>
            <ArticleId IdType="pmc">PMC3980601</ArticleId>
            <ArticleId IdType="pubmed">24518612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang Y, Li Y, Song L, Alvarez AA, Zhang W, Lv D, Tang J, Liu F, Chang Z, Hatakeyama S, Hu B, Cheng SY, Feng H. TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. Cancer Res. 2018;78(7):1792–1804. doi: 10.1158/0008-5472.CAN-17-2774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2774</ArticleId>
            <ArticleId IdType="pmc">PMC5882560</ArticleId>
            <ArticleId IdType="pubmed">29386185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Feng X, Zhang B, Li J, Xu X, Liu J, Wang X, Wang J, Tong X. Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells. J Neurooncol. 2014;120(1):33–41. doi: 10.1007/s11060-014-1529-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-014-1529-8</ArticleId>
            <ArticleId IdType="pubmed">25048528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Li Z, Zhang C, Zhang S, Ji Y, Chen F. Knockdown of PKCε expression inhibits growth, induces apoptosis and decreases invasiveness of human glioma cells partially through Stat3. J Mol Neurosci. 2015;55(1):21–31. doi: 10.1007/s12031-014-0341-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-014-0341-4</ArticleId>
            <ArticleId IdType="pubmed">24888992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A, Weis J. IL-6 is required for glioma development in a mouse model. Oncogene. 2004;23(19):3308–3316. doi: 10.1038/sj.onc.1207455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207455</ArticleId>
            <ArticleId IdType="pubmed">15064729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, Zhang J. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100(2):165–176. doi: 10.1007/s11060-010-0158-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0158-0</ArticleId>
            <ArticleId IdType="pubmed">20361349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Sakurai Y, Ryu T, et al.  Expression of Rb2/p130 protein correlates with the degree of malignancy in gliomas. Brain Tumor Pathol. 2004;21:121–125. doi: 10.1007/BF02482187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02482187</ArticleId>
            <ArticleId IdType="pubmed">15696973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 2009;9(5):580–590. doi: 10.2174/156652409788488739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156652409788488739</ArticleId>
            <ArticleId IdType="pmc">PMC2712135</ArticleId>
            <ArticleId IdType="pubmed">19601808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019;8(11):1398. doi: 10.3390/cells8111398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8111398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J, Shim JK, Yoon SJ, et al.  Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. Sci Rep. 2019;9:10555. doi: 10.1038/s41598-019-47066-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-47066-y</ArticleId>
            <ArticleId IdType="pmc">PMC6646357</ArticleId>
            <ArticleId IdType="pubmed">31332251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West AJ, Tsui V, Stylli SS, Nguyen HPT, Morokoff AP, Kaye AH, Luwor RB. The role of interleukin-6-STAT3 signalling in glioblastoma. Oncol Lett. 2018;16(4):4095–4104. doi: 10.3892/ol.2018.9227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.9227</ArticleId>
            <ArticleId IdType="pmc">PMC6144698</ArticleId>
            <ArticleId IdType="pubmed">30250528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weis J, Schönrock LM, Züchner SL, Lie DC, Sure U, Schul C, Stögbauer F, Ringelstein EB, Halfter H. CNTF and its receptor subunits in human gliomas. J Neurooncol. 1999;44(3):243–253. doi: 10.1023/a:1006303221064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1006303221064</ArticleId>
            <ArticleId IdType="pubmed">10720204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315–327. doi: 10.1016/j.ccr.2009.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.02.011</ArticleId>
            <ArticleId IdType="pubmed">19345330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J, Ksendzovsky A, Yang C, et al.  CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation. J Neurosurg. 2012;117(6):1022–1031. doi: 10.3171/2012.9.JNS1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2012.9.JNS1212</ArticleId>
            <ArticleId IdType="pmc">PMC4762039</ArticleId>
            <ArticleId IdType="pubmed">23061382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang L, Zhang IY, Chen X, Da Fonseca A, Wu S, Ren H, Badie S, Sadeghi S, Ouyang M, Warden CD, Badie B. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res. 2013;19(14):3764–3775. doi: 10.1158/1078-0432.CCR-12-3725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-3725</ArticleId>
            <ArticleId IdType="pmc">PMC3725731</ArticleId>
            <ArticleId IdType="pubmed">23719262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulleman E, Quarto M, Vernell R, et al.  A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med. 2009;13(1):136–146. doi: 10.1111/j.1582-4934.2008.00307.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1582-4934.2008.00307.x</ArticleId>
            <ArticleId IdType="pmc">PMC3823042</ArticleId>
            <ArticleId IdType="pubmed">18363832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, Simonelli M, Colombo P, Baena y Rodriguez R. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori. 2010;96(1):97–102. doi: 10.1177/030089161009600116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/030089161009600116</ArticleId>
            <ArticleId IdType="pubmed">20437865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsung AJ, Guda MR, Asuthkar S, Labak CM, Purvis IJ, Lu Y, Jain N, Bach SE, Prasad DVR, Velpula KK. Methylation regulates HEY1 expression in glioblastoma. Oncotarget. 2017;8(27):44398–44409. doi: 10.18632/oncotarget.17897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.17897</ArticleId>
            <ArticleId IdType="pmc">PMC5546488</ArticleId>
            <ArticleId IdType="pubmed">28574840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brun M, Jain S, Monckton EA, Godbout R. Nuclear factor I represses the notch effector HEY1 in glioblastoma. Neoplasia. 2018;20(10):1023–1037. doi: 10.1016/j.neo.2018.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2018.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC6138789</ArticleId>
            <ArticleId IdType="pubmed">30195713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayanappa R, Rout P, Aithal MG, Chand AK. Aberrant expression of Notch1, HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues. Tumour Biol. 2016;37(5):6935–6942. doi: 10.1007/s13277-015-4592-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-015-4592-7</ArticleId>
            <ArticleId IdType="pubmed">26662803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenciarelli C, Marei HE, Zonfrillo M, Casalbore P, Felsani A, Giannetti S, Trevisi G, Althani A, Mangiola A. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets. Oncotarget. 2017;8(11):17873–17886. doi: 10.18632/oncotarget.15013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15013</ArticleId>
            <ArticleId IdType="pmc">PMC5392293</ArticleId>
            <ArticleId IdType="pubmed">28157712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haapa-Paananen S, Kiviluoto S, Waltari M, Puputti M, Mpindi JP, Kohonen P, Tynninen O, Haapasalo H, Joensuu H, Perälä M, Kallioniemi O. HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene. 2012;31(10):1299–1310. doi: 10.1038/onc.2011.316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.316</ArticleId>
            <ArticleId IdType="pubmed">21785461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther. 2015;16(3):353–359. doi: 10.1080/15384047.2015.1016662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384047.2015.1016662</ArticleId>
            <ArticleId IdType="pmc">PMC4622741</ArticleId>
            <ArticleId IdType="pubmed">25781910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soubannier V, Stifani S. NF-κB signalling in glioblastoma. Biomedicines. 2017;5(2):29. doi: 10.3390/biomedicines5020029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines5020029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan K, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013;26(6):701–707. doi: 10.1097/WCO.0000000000000032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000032</ArticleId>
            <ArticleId IdType="pmc">PMC4031658</ArticleId>
            <ArticleId IdType="pubmed">24152818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cahill KE, Morshed RA, Yamini B. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. Neuro-Oncology. 2015;18(3):329–339. doi: 10.1093/neuonc/nov265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov265</ArticleId>
            <ArticleId IdType="pmc">PMC4767244</ArticleId>
            <ArticleId IdType="pubmed">26534766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fallon KB, Havlioglu N, Hamilton LH, Cheng TP, Carroll SL. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neurooncol. 2004;66(3):273–284. doi: 10.1023/b:neon.0000014521.28294.84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/b:neon.0000014521.28294.84</ArticleId>
            <ArticleId IdType="pubmed">15015657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin WW, Ou GY, Lin JZ, Yi SJ, Yao WC, Pan HC, Zhao WJ. Neuregulin 1 enhances cell adhesion molecule L1 like expression levels and promotes malignancy in human glioma. Oncol Lett. 2020;20(1):326–336. doi: 10.3892/ol.2020.11548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2020.11548</ArticleId>
            <ArticleId IdType="pmc">PMC7285836</ArticleId>
            <ArticleId IdType="pubmed">32565959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao WJ, Schachner M. Neuregulin 1 enhances cell adhesion molecule l1 expression in human glioma cells and promotes their migration as a function of malignancy. J Neuropathol Exp Neurol. 2013;72(3):244–255. doi: 10.1097/NEN.0b013e3182863dc5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e3182863dc5</ArticleId>
            <ArticleId IdType="pubmed">23399902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritch PS, Carroll SL, Sontheimer H. Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia. 2005;51(3):217–228. doi: 10.1002/glia.20197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20197</ArticleId>
            <ArticleId IdType="pmc">PMC2548407</ArticleId>
            <ArticleId IdType="pubmed">15812817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Achenbach C, Weller M, Szabo E. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. J Neurochem. 2018;147(1):99–109. doi: 10.1111/jnc.14538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14538</ArticleId>
            <ArticleId IdType="pubmed">29953622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donaires FS, Godoy PR, Leandro GS, Puthier D, Sakamoto-Hojo ET. E2F transcription factors associated with up-regulated genes in glioblastoma. Cancer Biomark. 2017;18(2):199–208. doi: 10.3233/CBM-161628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/CBM-161628</ArticleId>
            <ArticleId IdType="pubmed">27983535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orozco-Morales M, Sánchez-García FJ, Golán-Cancela I, Hernández-Pedro N, Costoya JA, de la Cruz VP, Moreno-Jiménez S, Sotelo J, Pineda B. RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells. Cancer Cell Int. 2015;15:57. doi: 10.1186/s12935-015-0209-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-015-0209-x</ArticleId>
            <ArticleId IdType="pmc">PMC4491266</ArticleId>
            <ArticleId IdType="pubmed">26146488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip W, Shao W, Chiang YT, Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. Am J Physiol Endocrinol Metab. 2012;303(9):E1166–E1176. doi: 10.1152/ajpendo.00249.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00249.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3492858</ArticleId>
            <ArticleId IdType="pubmed">22967502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreira S, Polena E, Gordon V, Abdulla S, Mahendram S, Cao J, Blais A, Wood GA, Dvorkin-Gheva A, Doble BW. A single TCF transcription factor, regardless of its activation capacity, is sufficient for effective trilineage differentiation of ESCs. Cell Rep. 2017;20(10):2424–2438. doi: 10.1016/j.celrep.2017.08.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.08.043</ArticleId>
            <ArticleId IdType="pubmed">28877475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doumpas N, Lampart F, Robinson MD, et al.  TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. EMBO J. 2019;38(2):e98873. doi: 10.15252/embj.201798873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201798873</ArticleId>
            <ArticleId IdType="pmc">PMC6331726</ArticleId>
            <ArticleId IdType="pubmed">30425074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014;32(6):190–201. doi: 10.3109/08977194.2014.985787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08977194.2014.985787</ArticleId>
            <ArticleId IdType="pmc">PMC4693299</ArticleId>
            <ArticleId IdType="pubmed">25418012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ylivinkka I, Sihto H, Tynninen O, et al.  Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness. J Exp Clin Cancer Res. 2017;36:9. doi: 10.1186/s13046-016-0482-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0482-0</ArticleId>
            <ArticleId IdType="pmc">PMC5223529</ArticleId>
            <ArticleId IdType="pubmed">28069038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Ge R, Zhou J, et al.  Nuclear factor IX promotes glioblastoma development through transcriptional activation of Ezrin. Oncogenesis. 2020;9(4):39. doi: 10.1038/s41389-020-0223-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41389-020-0223-2</ArticleId>
            <ArticleId IdType="pmc">PMC7156762</ArticleId>
            <ArticleId IdType="pubmed">32291386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang W. The role of HOPX in normal tissues and tumor progression. Biosci Rep. 2020;40(1):BSR20191953. doi: 10.1042/BSR20191953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20191953</ArticleId>
            <ArticleId IdType="pmc">PMC6997107</ArticleId>
            <ArticleId IdType="pubmed">31934721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Toni A, Zbinden M, Epstein JA, Ruiz i Altaba A, Prochiantz A, Caillé I. Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP. Neural Dev. 2008;3:13. doi: 10.1186/1749-8104-3-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1749-8104-3-13</ArticleId>
            <ArticleId IdType="pmc">PMC2416439</ArticleId>
            <ArticleId IdType="pubmed">18507846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity [published correction appears in Curr Biol. 2007 Jan 23;17(2):192] Curr Biol. 2007;17(2):165–172. doi: 10.1016/j.cub.2006.11.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2006.11.033</ArticleId>
            <ArticleId IdType="pmc">PMC1855204</ArticleId>
            <ArticleId IdType="pubmed">17196391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lino MM, Merlo A, Boulay JL. Notch signaling in glioblastoma: a developmental drug target? BMC Med. 2010;8:72. doi: 10.1186/1741-7015-8-72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-8-72</ArticleId>
            <ArticleId IdType="pmc">PMC2996337</ArticleId>
            <ArticleId IdType="pubmed">21078177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazzoni R, Bentivegna A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel). 2019;11(3):292. doi: 10.3390/cancers11030292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11030292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiu MX, Liu YM, Kuang BH. The role of DLLs in cancer: a novel therapeutic target. Onco Targets Ther. 2020;13:3881–3901. doi: 10.2147/OTT.S244860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S244860</ArticleId>
            <ArticleId IdType="pmc">PMC7213894</ArticleId>
            <ArticleId IdType="pubmed">32440154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Hindy N, Keyvani K, Pagenstecher A, et al.  Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol. 2013;15(10):1366–1378. doi: 10.1093/neuonc/not071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not071</ArticleId>
            <ArticleId IdType="pmc">PMC3779034</ArticleId>
            <ArticleId IdType="pubmed">23787764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockhausen MT, Kristoffersen K, Poulsen HS. The functional role of Notch signaling in human gliomas. Neuro Oncol. 2010;12(2):199–211. doi: 10.1093/neuonc/nop022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nop022</ArticleId>
            <ArticleId IdType="pmc">PMC2940575</ArticleId>
            <ArticleId IdType="pubmed">20150387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J, Nakazato Y. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol. 2012;29(3):160–167. doi: 10.1007/s10014-012-0081-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10014-012-0081-5</ArticleId>
            <ArticleId IdType="pubmed">22350668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun. 2013;433(4):496–501. doi: 10.1016/j.bbrc.2013.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.03.021</ArticleId>
            <ArticleId IdType="pubmed">23524267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matini AH, Mofidi Naeini M, Haddad Kashani H, Vakili Z. Evaluation of Nestin and EGFR in patients with glioblastoma multiforme in a public hospital in Iran. Asian Pac J Cancer Prev. 2020;21(10):2889–2894. doi: 10.31557/APJCP.2020.21.10.2889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2020.21.10.2889</ArticleId>
            <ArticleId IdType="pmc">PMC7798165</ArticleId>
            <ArticleId IdType="pubmed">33112545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gersey Z, Osiason AD, Bloom L, Shah S, Thompson JW, Bregy A, Agarwal N, Komotar RJ. Therapeutic targeting of the notch pathway in glioblastoma multiforme. World Neurosurg. 2019;131:252–263.e2. doi: 10.1016/j.wneu.2019.07.180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2019.07.180</ArticleId>
            <ArticleId IdType="pubmed">31376551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget. 2016;7(27):41251–41264. doi: 10.18632/oncotarget.9275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9275</ArticleId>
            <ArticleId IdType="pmc">PMC5173056</ArticleId>
            <ArticleId IdType="pubmed">27183910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Liu Z, Jiang B, Peng R, Ma Z, Lu J. SOX9 overexpression promotes glioma metastasis via Wnt/β-catenin signaling. Cell Biochem Biophys. 2015;73(1):205–212. doi: 10.1007/s12013-015-0647-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12013-015-0647-z</ArticleId>
            <ArticleId IdType="pubmed">25716338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, Tu Y, Zhang Y. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29(5):3484–3490. doi: 10.1007/s12032-012-0267-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-012-0267-z</ArticleId>
            <ArticleId IdType="pubmed">22714060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Rocha AM, Sampron N, Alonso MM, Matheu A. Role of SOX family of transcription factors in central nervous system tumors. Am J Cancer Res. 2014;4(4):312–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4106650</ArticleId>
            <ArticleId IdType="pubmed">25057435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komada M. Sonic hedgehog signaling coordinates the proliferation and differentiation of neural stem/progenitor cells by regulating cell cycle kinetics during development of the neocortex. Congenit Anom (Kyoto). 2012;52(2):72–77. doi: 10.1111/j.1741-4520.2012.00368.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1741-4520.2012.00368.x</ArticleId>
            <ArticleId IdType="pubmed">22639991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carballo GB, Honorato JR, de Lopes GPF, Spohr TCLSE. A highlight on Sonic hedgehog pathway. Cell Commun Signal. 2018;16(1):11. doi: 10.1186/s12964-018-0220-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-018-0220-7</ArticleId>
            <ArticleId IdType="pmc">PMC5861627</ArticleId>
            <ArticleId IdType="pubmed">29558958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hung HC, Liu CC, Chuang JY, Su CL, Gean PW. Inhibition of sonic hedgehog signaling suppresses glioma stem-like cells likely through inducing autophagic cell death. Front Oncol. 2020;10:1233. doi: 10.3389/fonc.2020.01233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01233</ArticleId>
            <ArticleId IdType="pmc">PMC7393230</ArticleId>
            <ArticleId IdType="pubmed">32793494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariyath MPM, Shahi MH, Farheen S, Tayyab M, Khanam N, Ali A. Novel homeodomain transcription factor Nkx2.2 in the brain tumor development. Curr Cancer Drug Targets. 2020;20(5):335–340. doi: 10.2174/1568009618666180102111539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568009618666180102111539</ArticleId>
            <ArticleId IdType="pubmed">29295693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013;19(11):1518–1523. doi: 10.1038/nm.3328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3328</ArticleId>
            <ArticleId IdType="pmc">PMC3923315</ArticleId>
            <ArticleId IdType="pubmed">24076665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt MJ, Company C, Dramaretska Y, Barozzi I, Göhrig A, Kertalli S, Großmann M, Naumann H, Sanchez-Bailon MP, Hulsman D, Glass R, Squatrito M, Serresi M, Gargiulo G. Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing. Cancer Discov. 2021;11(3):754–777. doi: 10.1158/2159-8290.CD-20-0219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-20-0219</ArticleId>
            <ArticleId IdType="pmc">PMC7611210</ArticleId>
            <ArticleId IdType="pubmed">33361384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajetto A, Thellung S, Dellacasagrande I, Pagano A, Barbieri F, Florio T. Cross talk between mesenchymal and glioblastoma stem cells: communication beyond controversies. Stem Cells Transl Med. 2020;9(11):1310–1330. doi: 10.1002/sctm.20-0161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sctm.20-0161</ArticleId>
            <ArticleId IdType="pmc">PMC7581451</ArticleId>
            <ArticleId IdType="pubmed">32543030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes Dev. 2017;31(12):1212–1227. doi: 10.1101/gad.300079.117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.300079.117</ArticleId>
            <ArticleId IdType="pmc">PMC5558924</ArticleId>
            <ArticleId IdType="pubmed">28724615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guichet PO, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, Scamps F, Ripoll C, Vacher S, Taviaux S, Chevassus H, Duffau H, Mallet J, Susini A, Joubert D, Bauchet L, Hugnot JP. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013;61(2):225–239. doi: 10.1002/glia.22429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.22429</ArticleId>
            <ArticleId IdType="pubmed">23047160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Z, Zang T, Liu ML, Wang LL, Niu W, Zhang CL. Reprogramming the fate of human glioma cells to impede brain tumor development. Cell Death Dis. 2014;5(10):e1463. doi: 10.1038/cddis.2014.425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.425</ArticleId>
            <ArticleId IdType="pmc">PMC4649522</ArticleId>
            <ArticleId IdType="pubmed">25321470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Pei Z, Hossain A, Bai Y, Chen G. Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion. Cancer Biol Med. 2021. 10.20892/j.issn.2095-3941.2020.0499 Epub ahead of print. PMID: 33755378.</Citation>
        </Reference>
        <Reference>
          <Citation>Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O'Rourke DM. SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol. 2017;135(3):487–496. doi: 10.1007/s11060-017-2610-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2610-x</ArticleId>
            <ArticleId IdType="pubmed">28852935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Xing H, Kim TM, et al.  Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells. 2012;30(7):1313–1326. doi: 10.1002/stem.1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1120</ArticleId>
            <ArticleId IdType="pmc">PMC3963835</ArticleId>
            <ArticleId IdType="pubmed">22553175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Euskirchen P, Skaftnesmo KO, Huszthy PC, Brekkå N, Bjerkvig R, Jacobs AH, Miletic H. NUMB does not impair growth and differentiation status of experimental gliomas. Exp Cell Res. 2011;317(20):2864–2873. doi: 10.1016/j.yexcr.2011.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2011.09.002</ArticleId>
            <ArticleId IdType="pubmed">21939656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung HH, Lee CT, Hu JM, Chou YC, Lin YW, Shih YL. NKX6.1 represses tumorigenesis, metastasis, and chemoresistance in colorectal cancer. Int J Mol Sci. 2020;21(14):5106. doi: 10.3390/ijms21145106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21145106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li HJ, Yu PN, Huang KY, Su HY, Hsiao TH, Chang CP, Yu MH, Lin YW. NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene. 2016;35(17):2266–2278. doi: 10.1038/onc.2015.289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.289</ArticleId>
            <ArticleId IdType="pmc">PMC4855079</ArticleId>
            <ArticleId IdType="pubmed">26257059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park NI, Guilhamon P, Desai K, RF MA, Langille E, O'Connor M, Lan X, Whetstone H, Coutinho FJ, Vanner RJ, Ling E, Prinos P, Lee L, Selvadurai H, Atwal G, Kushida M, Clarke ID, Voisin V, Cusimano MD, Bernstein M, Das S, Bader G, Arrowsmith CH, Angers S, Huang X, Lupien M, Dirks PB. ASCL1 reorganizes chromatin to direct neuronal fate and suppress tumorigenicity of glioblastoma stem cells. Cell Stem Cell. 2017;21(2):209–224.e7. doi: 10.1016/j.stem.2017.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2017.06.004</ArticleId>
            <ArticleId IdType="pubmed">28712938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao D. Emerging roles of the EBF family of transcription factors in tumor suppression. Mol Cancer Res. 2009;7(12):1893–1901. doi: 10.1158/1541-7786.MCR-09-0229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-09-0229</ArticleId>
            <ArticleId IdType="pmc">PMC5545892</ArticleId>
            <ArticleId IdType="pubmed">19996307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melhuish TA, Kowalczyk I, Manukyan A, Zhang Y, Shah A, Abounader R, Wotton D. Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech. 2018;1861(11):983–995. doi: 10.1016/j.bbagrm.2018.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagrm.2018.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC6203443</ArticleId>
            <ArticleId IdType="pubmed">30312684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawn S, Krishna N, Pisklakova A, et al.  Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem. 2015;290(6):3814–3824. doi: 10.1074/jbc.M114.599373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.599373</ArticleId>
            <ArticleId IdType="pmc">PMC4319045</ArticleId>
            <ArticleId IdType="pubmed">25538243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, Wu J, Xu X, Fu L, Li Y, Yang J, Zhang W, Bai R, Yi F, Suzuki K, Gao H, Esteban CR, Zhang C, Izpisua Belmonte JC, Chen Z, Wang X, Jiang T, Qu J, Tang F, Liu GH. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun. 2015;6:10068. doi: 10.1038/ncomms10068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10068</ArticleId>
            <ArticleId IdType="pmc">PMC4686761</ArticleId>
            <ArticleId IdType="pubmed">26632666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu YT, Li BF, Zhang PJ, et al.  Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines via regulating Shh-Gli1 signaling. World J Gastroenterol. 2019;25(8):923–940. doi: 10.3748/wjg.v25.i8.923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v25.i8.923</ArticleId>
            <ArticleId IdType="pmc">PMC6397724</ArticleId>
            <ArticleId IdType="pubmed">30833799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sangpairoj K, Vivithanaporn P, Apisawetakan S, Chongthammakun S, Sobhon P, Chaithirayanon K. RUNX1 regulates migration, invasion, and angiogenesis via p38 MAPK pathway in human glioblastoma. Cell Mol Neurobiol. 2017;37(7):1243–1255. doi: 10.1007/s10571-016-0456-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10571-016-0456-y</ArticleId>
            <ArticleId IdType="pubmed">28012022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada D, Fujikawa K, Kawabe K, Furuta T, Nakada M, Takarada T. RUNX2 promotes malignant progression in glioma. Neurochem Res. 2018;43(11):2047–2054. doi: 10.1007/s11064-018-2626-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-018-2626-4</ArticleId>
            <ArticleId IdType="pubmed">30203400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest. 2016;96(2):137–150. doi: 10.1038/labinvest.2015.140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2015.140</ArticleId>
            <ArticleId IdType="pubmed">26641068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shevchenko V, Arnotskaya N, Korneyko M, Zaytsev S, Khotimchenko Y, Sharma H, Bryukhovetskiy I. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma. Oncol Rep. 2019;41(5):3080–3088. doi: 10.3892/or.2019.7043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7043</ArticleId>
            <ArticleId IdType="pubmed">30864699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt pathway to defining biology of glioblastoma. Neuromolecular Med. 2018;20(4):437–451. doi: 10.1007/s12017-018-8514-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-018-8514-x</ArticleId>
            <ArticleId IdType="pubmed">30259273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotliarova S, Pastorino S, Kovell LC, et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008;68(16):6643–6651. doi: 10.1158/0008-5472.CAN-08-0850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-0850</ArticleId>
            <ArticleId IdType="pmc">PMC2585745</ArticleId>
            <ArticleId IdType="pubmed">18701488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proctor CJ, Gray DA. GSK3 and p53 - is there a link in Alzheimer’s disease? Mol Neurodegener. 2010;5:7. doi: 10.1186/1750-1326-5-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1326-5-7</ArticleId>
            <ArticleId IdType="pmc">PMC2831894</ArticleId>
            <ArticleId IdType="pubmed">20181016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WY, Snider WD. Functions of GSK-3 signaling in development of the nervous system. Front Mol Neurosci. 2011;4:44. doi: 10.3389/fnmol.2011.00044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2011.00044</ArticleId>
            <ArticleId IdType="pmc">PMC3221276</ArticleId>
            <ArticleId IdType="pubmed">22125510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YT, Hur EM, Snider WD, Zhou FQ. Role of GSK3 signaling in neuronal morphogenesis. Front Mol Neurosci. 2011;4:48. doi: 10.3389/fnmol.2011.00048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2011.00048</ArticleId>
            <ArticleId IdType="pmc">PMC3222852</ArticleId>
            <ArticleId IdType="pubmed">22131966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11(8):539–551. doi: 10.1038/nrn2870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2870</ArticleId>
            <ArticleId IdType="pmc">PMC3533361</ArticleId>
            <ArticleId IdType="pubmed">20648061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majewska E, Szeliga M. AKT/GSK3β signaling in glioblastoma. Neurochem Res. 2017;42(3):918–924. doi: 10.1007/s11064-016-2044-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-016-2044-4</ArticleId>
            <ArticleId IdType="pmc">PMC5357492</ArticleId>
            <ArticleId IdType="pubmed">27568206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domoto T, Uehara M, Bolidong D, Minamoto T. Glycogen synthase kinase 3β in cancer biology and treatment. Cells. 2020;9(6):1388. doi: 10.3390/cells9061388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9061388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenci T, Martini M, Montano N, D'Alessandris QG, Falchetti ML, Annibali D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. Am J Clin Pathol. 2012;138(3):390–396. doi: 10.1309/AJCPRXHNJQLO09QA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPRXHNJQLO09QA</ArticleId>
            <ArticleId IdType="pubmed">22912356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins DM, Wang R, Milligan B, Schroeder M, Carlson B, Pokorny J, Cheshier SH, Meyer FB, Weissman IL, Sarkaria JN, Henley JR. Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget. 2013;4(5):792–801. doi: 10.18632/oncotarget.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1059</ArticleId>
            <ArticleId IdType="pmc">PMC3742839</ArticleId>
            <ArticleId IdType="pubmed">23801022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray SK. The transcription regulator Krüppel-like factor 4 and its dual roles of oncogene in glioblastoma and tumor suppressor in neuroblastoma. For Immunopathol Dis Therap. 2016;7(1-2):127–139. doi: 10.1615/ForumImmunDisTher.2016017227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/ForumImmunDisTher.2016017227</ArticleId>
            <ArticleId IdType="pmc">PMC5423539</ArticleId>
            <ArticleId IdType="pubmed">28497005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson E, Zhai Q, Zeng ZJ, Yoshida T, Funa K. Nuclear receptor TLX inhibits TGF-β signaling in glioblastoma. Exp Cell Res. 2016;343(2):118–125. doi: 10.1016/j.yexcr.2016.03.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2016.03.028</ArticleId>
            <ArticleId IdType="pubmed">27048878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Niu W, Qin S, Downes M, Burns DK, Zhang CL. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche. Mol Cell Biol. 2012;32(23):4811–4820. doi: 10.1128/MCB.01122-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01122-12</ArticleId>
            <ArticleId IdType="pmc">PMC3497606</ArticleId>
            <ArticleId IdType="pubmed">23028043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodorou E, Dalembert G, Heffelfinger C, et al.  A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. Genes Dev. 2009;23(5):575–588. doi: 10.1101/gad.1772509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1772509</ArticleId>
            <ArticleId IdType="pmc">PMC2658525</ArticleId>
            <ArticleId IdType="pubmed">19270158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tantin D. Oct transcription factors in development and stem cells: insights and mechanisms. Development. 2013;140(14):2857–2866. doi: 10.1242/dev.095927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.095927</ArticleId>
            <ArticleId IdType="pmc">PMC3699277</ArticleId>
            <ArticleId IdType="pubmed">23821033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira AI, Anjo SI, Vieira de Castro J, Serra SC, Salgado AJ, Manadas B, Costa BM. Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells. Cell Commun Signal. 2017;15(1):37. doi: 10.1186/s12964-017-0194-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-017-0194-x</ArticleId>
            <ArticleId IdType="pmc">PMC5625790</ArticleId>
            <ArticleId IdType="pubmed">28969644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucheryavykh LY, Rolón-Reyes K, Kucheryavykh YV, et al.  Glioblastoma development in mouse brain: general reduction of OCTs and mislocalization of OCT3 transporter and subsequent uptake of ASP+ substrate to the nuclei. J Neurosci Neuroeng. 2014;3(1):3–9. doi: 10.1166/jnsne.2014.1091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1166/jnsne.2014.1091</ArticleId>
            <ArticleId IdType="pmc">PMC4143131</ArticleId>
            <ArticleId IdType="pubmed">25165637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Qiu J, Zhang Z, et al.  SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study. Cell Biosci. 2021;11:23. doi: 10.1186/s13578-021-00539-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-021-00539-y</ArticleId>
            <ArticleId IdType="pmc">PMC7821488</ArticleId>
            <ArticleId IdType="pubmed">33482915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, Miyazono K. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem. 2011;286(48):41434–41441. doi: 10.1074/jbc.M111.300863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.300863</ArticleId>
            <ArticleId IdType="pmc">PMC3308855</ArticleId>
            <ArticleId IdType="pubmed">21987575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells. 2010;28(6):1019–1029. doi: 10.1002/stem.429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.429</ArticleId>
            <ArticleId IdType="pmc">PMC5532884</ArticleId>
            <ArticleId IdType="pubmed">20506127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu YY, Zheng MH, Cheng G, et al.  Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011;11:82. doi: 10.1186/1471-2407-11-82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-11-82</ArticleId>
            <ArticleId IdType="pmc">PMC3052197</ArticleId>
            <ArticleId IdType="pubmed">21342503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi L, Zhou X, Li T, et al.  Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 2019;38:339. doi: 10.1186/s13046-019-1319-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1319-4</ArticleId>
            <ArticleId IdType="pmc">PMC6683584</ArticleId>
            <ArticleId IdType="pubmed">31382985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 2018;23:12. doi: 10.1186/s11658-018-0078-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-018-0078-0</ArticleId>
            <ArticleId IdType="pmc">PMC5863838</ArticleId>
            <ArticleId IdType="pubmed">29588647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandru O, Horescu C, Sevastre AS, et al.  Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Contemp Oncol (Pozn). 2020;24(1):55–66. doi: 10.5114/wo.2020.94726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2020.94726</ArticleId>
            <ArticleId IdType="pmc">PMC7265959</ArticleId>
            <ArticleId IdType="pubmed">32514239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019;25(1):176–187. doi: 10.1038/s41591-018-0263-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0263-8</ArticleId>
            <ArticleId IdType="pmc">PMC6857804</ArticleId>
            <ArticleId IdType="pubmed">30531922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DY, Yeh TH, Emnett RJ, White CR, Gutmann DH. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev. 2010;24(20):2317–2329. doi: 10.1101/gad.1957110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1957110</ArticleId>
            <ArticleId IdType="pmc">PMC2956210</ArticleId>
            <ArticleId IdType="pubmed">20876733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YH, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes Dev. 2015;29(16):1677–1682. doi: 10.1101/gad.261677.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.261677.115</ArticleId>
            <ArticleId IdType="pmc">PMC4561477</ArticleId>
            <ArticleId IdType="pubmed">26272820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012;150(4):816–830. doi: 10.1016/j.cell.2012.06.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.034</ArticleId>
            <ArticleId IdType="pmc">PMC3427010</ArticleId>
            <ArticleId IdType="pubmed">22901811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ, Phillips JJ, Weiss WA, Resnick AC, Gosline S, Banerjee J, Guinney J, Gnekow A, Kandels D, Foreman NK, Korshunov A, Ryzhova M, Massimi L, Gururangan S, Kieran MW, Wang Z, Fouladi M, Sato M, Øra I, Holm S, Markham SJ, Beck P, Jäger N, Wittmann A, Sommerkamp AC, Sahm F, Pfister SM, Gutmann DH. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1) Acta Neuropathol. 2021;141(4):605–617. doi: 10.1007/s00401-021-02276-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-021-02276-5</ArticleId>
            <ArticleId IdType="pubmed">33585982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jecrois ES, Zheng W, Bornhorst M, Li Y, Treisman DM, Muguyo D, Huynh S, Andrew SF, Wang Y, Jiang J, Pierce BR, Mao H, Krause MK, Friend A, Nadal-Nicolas F, Stasheff SF, Li W, Zong H, Packer RJ, Zhu Y. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. Dev Cell. 2021;56(20):2871–2885.e6. doi: 10.1016/j.devcel.2021.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2021.08.004</ArticleId>
            <ArticleId IdType="pubmed">34428430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, Suzuki Y, Mashiyama S, Uenohara H, Watanabe M, Kumabe T, Tominaga T. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol. 2018;35(1):10–18. doi: 10.1007/s10014-017-0302-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10014-017-0302-z</ArticleId>
            <ArticleId IdType="pubmed">29138945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aranha MM, Solá S, Low WC, Steer CJ, Rodrigues CM. Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J Cell Biochem. 2009;107(4):748–758. doi: 10.1002/jcb.22172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.22172</ArticleId>
            <ArticleId IdType="pubmed">19415678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Rielland M, Yalcin S, Ghaffari S. Regulation and function of FoxO transcription factors in normal and cancer stem cells: what have we learned? Curr Drug Targets. 2011;12(9):1267–1283. doi: 10.2174/138945011796150325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138945011796150325</ArticleId>
            <ArticleId IdType="pubmed">21443463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:925350. doi: 10.1155/2014/925350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/925350</ArticleId>
            <ArticleId IdType="pmc">PMC4016844</ArticleId>
            <ArticleId IdType="pubmed">24864265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Z, Ren L, Wu D, Yang X, Zhou Z, Nie Q, Jiang G, Xue S, Weng W, Qiu Y, Lin Y. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. Int J Cancer. 2017;140(12):2792–2804. doi: 10.1002/ijc.30690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30690</ArticleId>
            <ArticleId IdType="pubmed">28295288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau CJ, Koty Z, Nalbantoglu J. Differential response of glioma cells to FOXO1-directed therapy. Cancer Res. 2009;69(13):5433–5440. doi: 10.1158/0008-5472.CAN-08-4540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-4540</ArticleId>
            <ArticleId IdType="pubmed">19549905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells. 2011;29(9):1327–1337. doi: 10.1002/stem.696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.696</ArticleId>
            <ArticleId IdType="pubmed">21793107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Wang J, Jin T, Zhou Y, Chen Q. FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma. Biochem Biophys Res Commun. 2018;504(1):46–53. doi: 10.1016/j.bbrc.2018.08.118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.08.118</ArticleId>
            <ArticleId IdType="pubmed">30172378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong Y, Zhang Y, Xiong S, Williams-Villalobo AE. A glance of p53 functions in brain development, neural stem cells, and brain cancer. Biology (Basel). 2020;9(9):285. doi: 10.3390/biology9090285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biology9090285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi R, Giannini C, Sarkaria JN, et al.  p53 isoform profiling in glioblastoma and injured brain. Oncogene. 2013;32(26):3165–3174. doi: 10.1038/onc.2012.322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.322</ArticleId>
            <ArticleId IdType="pmc">PMC3904233</ArticleId>
            <ArticleId IdType="pubmed">22824800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin Navarro A, Pronk RJ, van der Geest AT, Oliynyk G, Nordgren A, Arsenian-Henriksson M, Falk A, Wilhelm M. p53 controls genomic stability and temporal differentiation of human neural stem cells and affects neural organization in human brain organoids. Cell Death Dis. 2020;11(1):52. doi: 10.1038/s41419-019-2208-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2208-7</ArticleId>
            <ArticleId IdType="pmc">PMC6978389</ArticleId>
            <ArticleId IdType="pubmed">31974372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Dube C, Gibert M, Jr, et al.  The p53 pathway in glioblastoma. Cancers (Basel) 2018;10(9):297. doi: 10.3390/cancers10090297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10090297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagpal J, Jamoona A, Gulati ND, Mohan A, Braun A, Murali R, Jhanwar-Uniyal M. Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res. 2006;26(6C):4633–4639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17214319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30–39. doi: 10.1016/j.ebiom.2016.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2016.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC4919535</ArticleId>
            <ArticleId IdType="pubmed">27428416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol. 1997;56(2):180–185. doi: 10.1097/00005072-199702000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-199702000-00009</ArticleId>
            <ArticleId IdType="pubmed">9034372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir. 2003;64(1):30–36. doi: 10.1055/s-2003-37149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2003-37149</ArticleId>
            <ArticleId IdType="pubmed">12582944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson KL, Slack RS. The Rb pathway in neurogenesis. Neuroreport. 2001;12(9):A55–A62. doi: 10.1097/00001756-200107030-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-200107030-00001</ArticleId>
            <ArticleId IdType="pubmed">11435948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res. 2005;94:1–27. doi: 10.1016/S0065-230X(05)94001-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-230X(05)94001-3</ArticleId>
            <ArticleId IdType="pubmed">16095998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson KL, Vanderluit JL, Hébert JM, et al.  Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development. EMBO J. 2002;21(13):3337–3346. doi: 10.1093/emboj/cdf338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdf338</ArticleId>
            <ArticleId IdType="pmc">PMC126087</ArticleId>
            <ArticleId IdType="pubmed">12093735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T, Goldstein M, Kim AH, Huang J. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncol Adv. 2020;2(1):vdaa126. doi: 10.1093/noajnl/vdaa126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/noajnl/vdaa126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. J Neurooncol. 2016;127(3):483–492. doi: 10.1007/s11060-016-2066-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-016-2066-4</ArticleId>
            <ArticleId IdType="pmc">PMC4835517</ArticleId>
            <ArticleId IdType="pubmed">26839018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012;14(7):870–881. doi: 10.1093/neuonc/nos114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos114</ArticleId>
            <ArticleId IdType="pmc">PMC3379801</ArticleId>
            <ArticleId IdType="pubmed">22711607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karpel-Massler G, Nguyen TTT, Shang E, Siegelin MD. Novel IDH1-targeted glioma therapies. CNS Drugs. 2019;33(12):1155–1166. doi: 10.1007/s40263-019-00684-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-019-00684-6</ArticleId>
            <ArticleId IdType="pmc">PMC7027940</ArticleId>
            <ArticleId IdType="pubmed">31768950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18(9):2490–2501. doi: 10.1158/1078-0432.CCR-11-2977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2977</ArticleId>
            <ArticleId IdType="pubmed">22415316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–1589. doi: 10.1038/s41416-020-0814-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-0814-x</ArticleId>
            <ArticleId IdType="pmc">PMC7250901</ArticleId>
            <ArticleId IdType="pubmed">32291392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–1153. doi: 10.2353/ajpath.2009.080958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2009.080958</ArticleId>
            <ArticleId IdType="pmc">PMC2671348</ArticleId>
            <ArticleId IdType="pubmed">19246647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17(1):45–52. doi: 10.1093/neuonc/nou158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou158</ArticleId>
            <ArticleId IdType="pmc">PMC4483052</ArticleId>
            <ArticleId IdType="pubmed">25140036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013;126(6):931–937. doi: 10.1007/s00401-013-1163-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-013-1163-0</ArticleId>
            <ArticleId IdType="pubmed">23955565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M. TERT promoter alterations in glioblastoma: a systematic review. Cancers (Basel). 2021;13(5):1147. doi: 10.3390/cancers13051147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051147</ArticleId>
            <ArticleId IdType="pmc">PMC7962450</ArticleId>
            <ArticleId IdType="pubmed">33800183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumgarten P, Harter PN, Tönjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kögel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zörnig M, Mittelbronn M. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2):205–216. doi: 10.1111/nan.12088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12088</ArticleId>
            <ArticleId IdType="pubmed">24117486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–722. doi: 10.18632/oncotarget.588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.588</ArticleId>
            <ArticleId IdType="pmc">PMC3443254</ArticleId>
            <ArticleId IdType="pubmed">22869205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297. doi: 10.1007/s13311-017-0519-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-017-0519-x</ArticleId>
            <ArticleId IdType="pmc">PMC5398991</ArticleId>
            <ArticleId IdType="pubmed">28281173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683–2710. doi: 10.1101/gad.1596707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1596707</ArticleId>
            <ArticleId IdType="pubmed">17974913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–122. doi: 10.1158/2326-6066.CIR-13-0028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0028</ArticleId>
            <ArticleId IdType="pmc">PMC3881271</ArticleId>
            <ArticleId IdType="pubmed">24409449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi: 10.1016/j.ccr.2009.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.12.020</ArticleId>
            <ArticleId IdType="pmc">PMC2818769</ArticleId>
            <ArticleId IdType="pubmed">20129251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci. 2019;20(11):2746. doi: 10.3390/ijms20112746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20112746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33(25):2735–2744. doi: 10.1200/JCO.2015.61.5005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.61.5005</ArticleId>
            <ArticleId IdType="pmc">PMC5015426</ArticleId>
            <ArticleId IdType="pubmed">26124478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro Oncol. 2019;21(1):59–70. doi: 10.1093/neuonc/noy120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy120</ArticleId>
            <ArticleId IdType="pmc">PMC6303485</ArticleId>
            <ArticleId IdType="pubmed">30053126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2012;50(4):301–321. doi: 10.5114/fn.2012.32361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/fn.2012.32361</ArticleId>
            <ArticleId IdType="pubmed">23319187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steponaitis G, Tamasauskas A. Mesenchymal and proneural subtypes of glioblastoma disclose branching based on GSC associated signature. Int J Mol Sci. 2021;22(9):4964. doi: 10.3390/ijms22094964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22094964</ArticleId>
            <ArticleId IdType="pmc">PMC8124327</ArticleId>
            <ArticleId IdType="pubmed">34066996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behnan J, Finocchiaro G, Hanna G. The landscape of the mesenchymal signature in brain tumours. Brain. 2019;142(4):847–866. doi: 10.1093/brain/awz044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz044</ArticleId>
            <ArticleId IdType="pmc">PMC6485274</ArticleId>
            <ArticleId IdType="pubmed">30946477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, Sönmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B. Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition. Cell Rep. 2016;17(11):2994–3009. doi: 10.1016/j.celrep.2016.11.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.11.056</ArticleId>
            <ArticleId IdType="pubmed">27974212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inda MM, Bonavia R, Seoane J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel) 2014;6(1):226–239. doi: 10.3390/cancers6010226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6010226</ArticleId>
            <ArticleId IdType="pmc">PMC3980595</ArticleId>
            <ArticleId IdType="pubmed">24473088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55. doi: 10.3389/fonc.2015.00055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2015.00055</ArticleId>
            <ArticleId IdType="pmc">PMC4347445</ArticleId>
            <ArticleId IdType="pubmed">25785247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers (Basel). 2021;13(4):761. doi: 10.3390/cancers13040761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13040761</ArticleId>
            <ArticleId IdType="pmc">PMC7918815</ArticleId>
            <ArticleId IdType="pubmed">33673104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White CW, 3rd, Fan X, Maynard JC, Wheatley EG, Bieri G, Couthouis J, Burlingame AL, Villeda SA. Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation. Proc Natl Acad Sci U S A. 2020;117(36):22214–22224. doi: 10.1073/pnas.2007439117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2007439117</ArticleId>
            <ArticleId IdType="pmc">PMC7486730</ArticleId>
            <ArticleId IdType="pubmed">32848054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, Kline CN, Banerjee A, Reddy A, Oberheim Bush NA, Chang S, Braunstein S, Chang EF, Raffel C, Gupta N, Sun PP, Kim JYH, Moes G, Alva E, Li R, Bruggers CS, Alashari M, Wetmore C, Garg S, Dishop M, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Berger MS, Costello JF, Perry A, Solomon DA. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. Acta Neuropathol. 2020;139(5):953–957. doi: 10.1007/s00401-020-02144-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-020-02144-8</ArticleId>
            <ArticleId IdType="pmc">PMC7183424</ArticleId>
            <ArticleId IdType="pubmed">32157385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr BA, Clay MR, Pinto EM, Kesserwan C. An update on the central nervous system manifestations of Li-Fraumeni syndrome. Acta Neuropathol. 2020;139(4):669–687. doi: 10.1007/s00401-019-02055-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-019-02055-3</ArticleId>
            <ArticleId IdType="pubmed">31468188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9(4):535–539. doi: 10.1586/ern.09.4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/ern.09.4</ArticleId>
            <ArticleId IdType="pubmed">19344304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolillo M, Comincini S, Schinelli S. In vitro glioblastoma models: a journey into the third dimension. Cancers (Basel). 2021;13(10):2449. doi: 10.3390/cancers13102449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13102449</ArticleId>
            <ArticleId IdType="pmc">PMC8157833</ArticleId>
            <ArticleId IdType="pubmed">34070023</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35538578</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-7819</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>World journal of surgical oncology</Title>
          <ISOAbbreviation>World J Surg Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.</ArticleTitle>
        <Pagination>
          <StartPage>146</StartPage>
          <MedlinePgn>146</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">146</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12957-022-02602-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Glioblastoma is one of the most aggressive tumors. The etiology and the factors determining its onset are not yet entirely known. This study investigates the origins of GBM, and for this purpose, it focuses primarily on developmental gliogenic processes. It also focuses on the impact of the related neurogenic developmental processes in glioblastoma oncogenesis. It also addresses why glial cells are at more risk of tumor development compared to neurons.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Databases including PubMed, MEDLINE, and Google Scholar were searched for published articles without any date restrictions, involving glioblastoma, gliogenesis, neurogenesis, stemness, neural stem cells, gliogenic signaling and pathways, neurogenic signaling and pathways, and astrocytogenic genes.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The origin of GBM is dependent on dysregulation in multiple genes and pathways that accumulatively converge the cells towards oncogenesis. There are multiple layers of steps in glioblastoma oncogenesis including the failure of cell fate-specific genes to keep the cells differentiated in their specific cell types such as p300, BMP, HOPX, and NRSF/REST. There are genes and signaling pathways that are involved in differentiation and also contribute to GBM such as FGFR3, JAK-STAT, and hey1. The genes that contribute to differentiation processes but also contribute to stemness in GBM include notch, Sox9, Sox4, c-myc gene overrides p300, and then GFAP, leading to upregulation of nestin, SHH, NF-κB, and others. GBM mutations pathologically impact the cell circuitry such as the interaction between Sox2 and JAK-STAT pathway, resulting in GBM development and progression.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Glioblastoma originates when the gene expression of key gliogenic genes and signaling pathways become dysregulated. This study identifies key gliogenic genes having the ability to control oncogenesis in glioblastoma cells, including p300, BMP, PAX6, HOPX, NRSF/REST, LIF, and TGF beta. It also identifies key neurogenic genes having the ability to control oncogenesis including PAX6, neurogenins including Ngn1, NeuroD1, NeuroD4, Numb, NKX6-1 Ebf, Myt1, and ASCL1. This study also postulates how aging contributes to the onset of glioblastoma by dysregulating the gene expression of NF-κB, REST/NRSF, ERK, AKT, EGFR, and others.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shafi</LastName>
            <ForeName>Ovais</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-0572-6129</Identifier>
            <AffiliationInfo>
              <Affiliation>Sindh Medical College - Jinnah Sindh Medical University / Dow University of Health Sciences, Karachi, Pakistan. dr.ovaisshafi@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Ghazia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Sindh Medical College - Jinnah Sindh Medical University / Dow University of Health Sciences, Karachi, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>World J Surg Oncol</MedlineTA>
        <NlmUniqueID>101170544</NlmUniqueID>
        <ISSNLinking>1477-7819</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C083431">SOX4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055751">SOXC Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055751" MajorTopicYN="N">SOXC Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aging</Keyword>
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma origins</Keyword>
        <Keyword MajorTopicYN="N">Gliogenesis</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Neurogenesis</Keyword>
        <Keyword MajorTopicYN="N">Oncogenesis</Keyword>
        <Keyword MajorTopicYN="N">Regeneration</Keyword>
        <Keyword MajorTopicYN="N">Stem cells</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>23</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35538578</ArticleId>
        <ArticleId IdType="pmc">PMC9087910</ArticleId>
        <ArticleId IdType="doi">10.1186/s12957-022-02602-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12957-022-02602-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–397. doi: 10.1016/B978-0-12-802997-8.00023-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-802997-8.00023-2</ArticleId>
            <ArticleId IdType="pubmed">26948367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme - an overview. Contemp Oncol (Pozn). 2014;18(5):307–312. doi: 10.5114/wo.2014.40559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2014.40559</ArticleId>
            <ArticleId IdType="pmc">PMC4248049</ArticleId>
            <ArticleId IdType="pubmed">25477751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48–56. doi: 10.3109/07357907.2011.630050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07357907.2011.630050</ArticleId>
            <ArticleId IdType="pmc">PMC3799884</ArticleId>
            <ArticleId IdType="pubmed">22236189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafi O. Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review. BMC Neurol. 2016;16:236. doi: 10.1186/s12883-016-0765-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-016-0765-2</ArticleId>
            <ArticleId IdType="pmc">PMC5120447</ArticleId>
            <ArticleId IdType="pubmed">27875990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–S8. doi: 10.1188/16.CJON.S1.2-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1188/16.CJON.S1.2-8</ArticleId>
            <ArticleId IdType="pmc">PMC5123811</ArticleId>
            <ArticleId IdType="pubmed">27668386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807–821. doi: 10.1038/nrc1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1208</ArticleId>
            <ArticleId IdType="pubmed">14557817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Liu Z, Balivada S, et al.  Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther. 2012;3:5. doi: 10.1186/scrt96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/scrt96</ArticleId>
            <ArticleId IdType="pmc">PMC3340549</ArticleId>
            <ArticleId IdType="pubmed">22330721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira-Nunes MC, Assad Kahn S, de Oliveira Barbeitas AL, et al.  The availability of the embryonic TGF-β protein Nodal is dynamically regulated during glioblastoma multiforme tumorigenesis. Cancer Cell Int. 2016;16:46. doi: 10.1186/s12935-016-0324-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-016-0324-3</ArticleId>
            <ArticleId IdType="pmc">PMC4912793</ArticleId>
            <ArticleId IdType="pubmed">27330409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Pan JQ, Luo L, et al.  NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi: 10.1186/1476-4598-14-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-14-2</ArticleId>
            <ArticleId IdType="pmc">PMC4429406</ArticleId>
            <ArticleId IdType="pubmed">25971746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi: 10.1056/NEJMra0708126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0708126</ArticleId>
            <ArticleId IdType="pubmed">18669428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev. 2006;17(1-2):29–40. doi: 10.1016/j.cytogfr.2005.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2005.09.006</ArticleId>
            <ArticleId IdType="pubmed">16289860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Son MJ, Woolard K, et al.  Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell. 2008;13(1):69–80. doi: 10.1016/j.ccr.2007.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2007.12.005</ArticleId>
            <ArticleId IdType="pmc">PMC2835498</ArticleId>
            <ArticleId IdType="pubmed">18167341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi G, Best B, Mania-Farnell B, James CD, Tomita T. Therapeutic potential for bone morphogenetic protein 4 in human malignant glioma. Neoplasia. 2017;19(4):261–270. doi: 10.1016/j.neo.2017.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC5342987</ArticleId>
            <ArticleId IdType="pubmed">28278424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sachdeva R, Wu M, Johnson K, Kim H, Celebre A, Shahzad U, Graham MS, Kessler JA, Chuang JH, Karamchandani J, Bredel M, Verhaak R, Das S. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Sci Rep. 2019;9(1):14569. doi: 10.1038/s41598-019-51270-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-51270-1</ArticleId>
            <ArticleId IdType="pmc">PMC6787003</ArticleId>
            <ArticleId IdType="pubmed">31602000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampazzo E, Dettin M, Maule F, Scabello A, Calvanese L, D'Auria G, Falcigno L, Porcù E, Zamuner A, Della Puppa A, Boso D, Basso G, Persano L. A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation. Biochim Biophys Acta Gen Subj. 2017;1861(9):2282–2292. doi: 10.1016/j.bbagen.2017.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2017.07.001</ArticleId>
            <ArticleId IdType="pubmed">28687190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-β signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4449428</ArticleId>
            <ArticleId IdType="pubmed">26045979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, Kim H. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22):7125–7134. doi: 10.1158/0008-5472.CAN-11-1330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1330</ArticleId>
            <ArticleId IdType="pubmed">21975932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-García A, Samsó P, Fontova P, Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U, Ventura F, Navarro-Sabaté À, Bartrons R. TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. FEBS J. 2017;284(20):3437–3454. doi: 10.1111/febs.14201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.14201</ArticleId>
            <ArticleId IdType="pubmed">28834297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegge B, Sjøttem E, Mikkola I. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress. BMC Cancer. 2018;18:496. doi: 10.1186/s12885-018-4394-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4394-6</ArticleId>
            <ArticleId IdType="pmc">PMC5930953</ArticleId>
            <ArticleId IdType="pubmed">29716531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol. 2005;71(3):223–229. doi: 10.1007/s11060-004-1720-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-004-1720-4</ArticleId>
            <ArticleId IdType="pubmed">15735909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molofsky AV, Krencik R, Ullian EM, et al.  Astrocytes and disease: a neurodevelopmental perspective [published correction appears in Genes Dev. 2012 Jul 1;26(13):1508. Krenick, Robert [corrected to Krencik, Robert]; Ullian, Erik [corrected to Ullian, Erik M]] Genes Dev. 2012;26(9):891–907. doi: 10.1101/gad.188326.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.188326.112</ArticleId>
            <ArticleId IdType="pmc">PMC3347787</ArticleId>
            <ArticleId IdType="pubmed">22549954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F, Yung WK, Zhou YH. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res. 2006;66(20):9809–9817. doi: 10.1158/0008-5472.CAN-05-3877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3877</ArticleId>
            <ArticleId IdType="pubmed">17047041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou YH, Hu Y, Mayes D, et al.  PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. J Neurooncol. 2010;96:191–200. doi: 10.1007/s11060-009-9963-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-009-9963-8</ArticleId>
            <ArticleId IdType="pmc">PMC2808537</ArticleId>
            <ArticleId IdType="pubmed">19618119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gómez-López S, Wiskow O, Favaro R, Nicolis SK, Price DJ, Pollard SM, Smith A. Sox2 and Pax6 maintain the proliferative and developmental potential of gliogenic neural stem cells In vitro. Glia. 2011;59(11):1588–1599. doi: 10.1002/glia.21201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.21201</ArticleId>
            <ArticleId IdType="pubmed">21766338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson TI, Price DJ. Pax6; a pleiotropic player in development. Bioessays. 2002;24(11):1041–1051. doi: 10.1002/bies.10174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bies.10174</ArticleId>
            <ArticleId IdType="pubmed">12386935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakurela S, Tiwari N, Schick S, et al.  Mapping gene regulatory circuitry of Pax6 during neurogenesis. Cell Discov. 2016;2:15045. doi: 10.1038/celldisc.2015.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/celldisc.2015.45</ArticleId>
            <ArticleId IdType="pmc">PMC4860964</ArticleId>
            <ArticleId IdType="pubmed">27462442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panicker SP, Raychaudhuri B, Sharma P, et al.  p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget. 2010;1(4):289–303. doi: 10.18632/oncotarget.100801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.100801</ArticleId>
            <ArticleId IdType="pmc">PMC3248108</ArticleId>
            <ArticleId IdType="pubmed">21304179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagalwala MN, Singh SK, Majumder S. Stemness is only a state of the cell. Cold Spring Harb Symp Quant Biol. 2008;73:227–234. doi: 10.1101/sqb.2008.73.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/sqb.2008.73.042</ArticleId>
            <ArticleId IdType="pubmed">19150961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu T, Aron L, Zullo J, et al.  REST and stress resistance in ageing and Alzheimer’s disease. Nature. 2014;507(7493):448–454. doi: 10.1038/nature13163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13163</ArticleId>
            <ArticleId IdType="pmc">PMC4110979</ArticleId>
            <ArticleId IdType="pubmed">24670762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamal MM, Sathyan P, Singh SK, Zinn PO, Marisetty AL, Liang S, Gumin J, El-Mesallamy HO, Suki D, Colman H, Fuller GN, Lang FF, Majumder S. REST regulates oncogenic properties of glioblastoma stem cells. Stem Cells. 2012;30(3):405–414. doi: 10.1002/stem.1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1020</ArticleId>
            <ArticleId IdType="pmc">PMC4039365</ArticleId>
            <ArticleId IdType="pubmed">22228704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Li Y, Wang R, Li Y, Shi P, Kan Z, Pang X. Inhibition of REST suppresses proliferation and migration in glioblastoma cells. Int J Mol Sci. 2016;17(5):664. doi: 10.3390/ijms17050664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17050664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marisetty AL, Lu L, Veo BL, et al.  REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Neuro Oncol. 2019;21(6):775–785. doi: 10.1093/neuonc/noz030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz030</ArticleId>
            <ArticleId IdType="pmc">PMC6556851</ArticleId>
            <ArticleId IdType="pubmed">30953587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang JY, Zukin RS. REST, a master transcriptional regulator in neurodegenerative disease. Curr Opin Neurobiol. 2018;48:193–200. doi: 10.1016/j.conb.2017.12.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.conb.2017.12.008</ArticleId>
            <ArticleId IdType="pmc">PMC5892838</ArticleId>
            <ArticleId IdType="pubmed">29351877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson R, Chan C. NRSF and its epigenetic effectors: new treatments for neurological disease. Brain Sci. 2018;8(12):–226. Published 2018 Dec 19. 10.3390/brainsci8120226.</Citation>
        </Reference>
        <Reference>
          <Citation>Halfter H, Kremerskothen J, Weber J, Hacker-Klom U, Barnekow A, Ringelstein EB, Stögbauer F. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. J Neurooncol. 1998;39(1):1–18. doi: 10.1023/a:1005901423332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1005901423332</ArticleId>
            <ArticleId IdType="pubmed">9760066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ardizzone A, Scuderi SA, Giuffrida D, Colarossi C, Puglisi C, Campolo M, Cuzzocrea S, Esposito E, Paterniti I. Role of fibroblast growth factors receptors (FGFRs) in brain tumors, focus on astrocytoma and glioblastoma. Cancers (Basel). 2020;12(12):3825. doi: 10.3390/cancers12123825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12123825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loilome W, Joshi AD, Rhys a CM, Piccirillo S, Vescovi AL, Gallia GL, Riggins GJ. Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol. 2009;94(3):359–366. doi: 10.1007/s11060-009-9885-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-009-9885-5</ArticleId>
            <ArticleId IdType="pubmed">19340397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jimenez-Pascual A, Siebzehnrubl FA. Fibroblast growth factor receptor functions in glioblastoma. Cells. 2019;8(7):715. doi: 10.3390/cells8070715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8070715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez AM, Berry M, Maher PA, Logan A, Baird A. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain Res. 1995;701(1-2):201–226. doi: 10.1016/0006-8993(95)01002-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(95)01002-x</ArticleId>
            <ArticleId IdType="pubmed">8925285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake A, Hattori Y, Ohta M, Itoh N. Rat oligodendrocytes and astrocytes preferentially express fibroblast growth factor receptor-2 and -3 mRNAs. J Neurosci Res. 1996;45(5):534–41. 10.1002/(SICI)1097-4547(19960901)45:5&lt;_x0035_34:_x003a_AIDJNR3&gt;3.0.CO;2-D.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohashi R, Matsuda Y, Ishiwata T, Naito Z. Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma. Oncol Rep. 2014;32(3):1163–1169. doi: 10.3892/or.2014.3283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2014.3283</ArticleId>
            <ArticleId IdType="pubmed">24968791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliva CR, Halloran B, Hjelmeland AB, et al.  IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell Commun Signal. 2018;16:61. doi: 10.1186/s12964-018-0273-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-018-0273-7</ArticleId>
            <ArticleId IdType="pmc">PMC6148802</ArticleId>
            <ArticleId IdType="pubmed">30231881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Carro MS, Curiel-García A, Campos C, Pourmaleki M, Grommes C, Vivanco I, Rohle D, Bielski CM, Taylor BS, Hollmann TJ, Rosenblum M, Tempst P, Blenis J, Squatrito M, Mellinghoff IK. EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nat Commun. 2017;8(1):2035. doi: 10.1038/s41467-017-02185-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02185-w</ArticleId>
            <ArticleId IdType="pmc">PMC5725448</ArticleId>
            <ArticleId IdType="pubmed">29229958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462–1466. doi: 10.1158/1078-0432.CCR-04-1737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1737</ArticleId>
            <ArticleId IdType="pubmed">15746047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ou A, Ott M, Fang D, Heimberger AB. The role and therapeutic targeting of JAK/STAT signaling in glioblastoma. Cancers (Basel). 2021;13(3):437. doi: 10.3390/cancers13030437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13030437</ArticleId>
            <ArticleId IdType="pmc">PMC7865703</ArticleId>
            <ArticleId IdType="pubmed">33498872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puram SV, Yeung CM, Jahani-Asl A, Lin C, de la Iglesia N, Konopka G, Jackson-Grusby L, Bonni A. STAT3-iNOS signaling mediates EGFRvIII-induced glial proliferation and transformation. J Neurosci. 2012;32(23):7806–7818. doi: 10.1523/JNEUROSCI.3243-11.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3243-11.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3409246</ArticleId>
            <ArticleId IdType="pubmed">22674257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE., Jr Stat3 as an oncogene. Cell. 1999;98(3):295–303. doi: 10.1016/s0092-8674(00)81959-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0092-8674(00)81959-5</ArticleId>
            <ArticleId IdType="pubmed">10458605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14(19):6042–6054. doi: 10.1158/1078-0432.CCR-07-4923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-4923</ArticleId>
            <ArticleId IdType="pmc">PMC2707832</ArticleId>
            <ArticleId IdType="pubmed">18829483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003;63(14):3923–3930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12873986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JE, Patel M, Ruzevick J, Jackson CM, Lim M. STAT3 activation in glioblastoma: biochemical and therapeutic implications. Cancers (Basel). 2014;6(1):376–395. doi: 10.3390/cancers6010376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6010376</ArticleId>
            <ArticleId IdType="pmc">PMC3980601</ArticleId>
            <ArticleId IdType="pubmed">24518612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang Y, Li Y, Song L, Alvarez AA, Zhang W, Lv D, Tang J, Liu F, Chang Z, Hatakeyama S, Hu B, Cheng SY, Feng H. TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. Cancer Res. 2018;78(7):1792–1804. doi: 10.1158/0008-5472.CAN-17-2774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2774</ArticleId>
            <ArticleId IdType="pmc">PMC5882560</ArticleId>
            <ArticleId IdType="pubmed">29386185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Feng X, Zhang B, Li J, Xu X, Liu J, Wang X, Wang J, Tong X. Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells. J Neurooncol. 2014;120(1):33–41. doi: 10.1007/s11060-014-1529-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-014-1529-8</ArticleId>
            <ArticleId IdType="pubmed">25048528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Li Z, Zhang C, Zhang S, Ji Y, Chen F. Knockdown of PKCε expression inhibits growth, induces apoptosis and decreases invasiveness of human glioma cells partially through Stat3. J Mol Neurosci. 2015;55(1):21–31. doi: 10.1007/s12031-014-0341-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-014-0341-4</ArticleId>
            <ArticleId IdType="pubmed">24888992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A, Weis J. IL-6 is required for glioma development in a mouse model. Oncogene. 2004;23(19):3308–3316. doi: 10.1038/sj.onc.1207455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207455</ArticleId>
            <ArticleId IdType="pubmed">15064729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, Zhang J. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100(2):165–176. doi: 10.1007/s11060-010-0158-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0158-0</ArticleId>
            <ArticleId IdType="pubmed">20361349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Sakurai Y, Ryu T, et al.  Expression of Rb2/p130 protein correlates with the degree of malignancy in gliomas. Brain Tumor Pathol. 2004;21:121–125. doi: 10.1007/BF02482187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02482187</ArticleId>
            <ArticleId IdType="pubmed">15696973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 2009;9(5):580–590. doi: 10.2174/156652409788488739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156652409788488739</ArticleId>
            <ArticleId IdType="pmc">PMC2712135</ArticleId>
            <ArticleId IdType="pubmed">19601808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019;8(11):1398. doi: 10.3390/cells8111398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8111398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J, Shim JK, Yoon SJ, et al.  Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. Sci Rep. 2019;9:10555. doi: 10.1038/s41598-019-47066-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-47066-y</ArticleId>
            <ArticleId IdType="pmc">PMC6646357</ArticleId>
            <ArticleId IdType="pubmed">31332251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West AJ, Tsui V, Stylli SS, Nguyen HPT, Morokoff AP, Kaye AH, Luwor RB. The role of interleukin-6-STAT3 signalling in glioblastoma. Oncol Lett. 2018;16(4):4095–4104. doi: 10.3892/ol.2018.9227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.9227</ArticleId>
            <ArticleId IdType="pmc">PMC6144698</ArticleId>
            <ArticleId IdType="pubmed">30250528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weis J, Schönrock LM, Züchner SL, Lie DC, Sure U, Schul C, Stögbauer F, Ringelstein EB, Halfter H. CNTF and its receptor subunits in human gliomas. J Neurooncol. 1999;44(3):243–253. doi: 10.1023/a:1006303221064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1006303221064</ArticleId>
            <ArticleId IdType="pubmed">10720204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315–327. doi: 10.1016/j.ccr.2009.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.02.011</ArticleId>
            <ArticleId IdType="pubmed">19345330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J, Ksendzovsky A, Yang C, et al.  CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation. J Neurosurg. 2012;117(6):1022–1031. doi: 10.3171/2012.9.JNS1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2012.9.JNS1212</ArticleId>
            <ArticleId IdType="pmc">PMC4762039</ArticleId>
            <ArticleId IdType="pubmed">23061382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang L, Zhang IY, Chen X, Da Fonseca A, Wu S, Ren H, Badie S, Sadeghi S, Ouyang M, Warden CD, Badie B. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res. 2013;19(14):3764–3775. doi: 10.1158/1078-0432.CCR-12-3725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-3725</ArticleId>
            <ArticleId IdType="pmc">PMC3725731</ArticleId>
            <ArticleId IdType="pubmed">23719262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulleman E, Quarto M, Vernell R, et al.  A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med. 2009;13(1):136–146. doi: 10.1111/j.1582-4934.2008.00307.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1582-4934.2008.00307.x</ArticleId>
            <ArticleId IdType="pmc">PMC3823042</ArticleId>
            <ArticleId IdType="pubmed">18363832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, Simonelli M, Colombo P, Baena y Rodriguez R. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori. 2010;96(1):97–102. doi: 10.1177/030089161009600116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/030089161009600116</ArticleId>
            <ArticleId IdType="pubmed">20437865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsung AJ, Guda MR, Asuthkar S, Labak CM, Purvis IJ, Lu Y, Jain N, Bach SE, Prasad DVR, Velpula KK. Methylation regulates HEY1 expression in glioblastoma. Oncotarget. 2017;8(27):44398–44409. doi: 10.18632/oncotarget.17897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.17897</ArticleId>
            <ArticleId IdType="pmc">PMC5546488</ArticleId>
            <ArticleId IdType="pubmed">28574840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brun M, Jain S, Monckton EA, Godbout R. Nuclear factor I represses the notch effector HEY1 in glioblastoma. Neoplasia. 2018;20(10):1023–1037. doi: 10.1016/j.neo.2018.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2018.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC6138789</ArticleId>
            <ArticleId IdType="pubmed">30195713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayanappa R, Rout P, Aithal MG, Chand AK. Aberrant expression of Notch1, HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues. Tumour Biol. 2016;37(5):6935–6942. doi: 10.1007/s13277-015-4592-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-015-4592-7</ArticleId>
            <ArticleId IdType="pubmed">26662803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenciarelli C, Marei HE, Zonfrillo M, Casalbore P, Felsani A, Giannetti S, Trevisi G, Althani A, Mangiola A. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets. Oncotarget. 2017;8(11):17873–17886. doi: 10.18632/oncotarget.15013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15013</ArticleId>
            <ArticleId IdType="pmc">PMC5392293</ArticleId>
            <ArticleId IdType="pubmed">28157712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haapa-Paananen S, Kiviluoto S, Waltari M, Puputti M, Mpindi JP, Kohonen P, Tynninen O, Haapasalo H, Joensuu H, Perälä M, Kallioniemi O. HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene. 2012;31(10):1299–1310. doi: 10.1038/onc.2011.316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.316</ArticleId>
            <ArticleId IdType="pubmed">21785461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther. 2015;16(3):353–359. doi: 10.1080/15384047.2015.1016662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384047.2015.1016662</ArticleId>
            <ArticleId IdType="pmc">PMC4622741</ArticleId>
            <ArticleId IdType="pubmed">25781910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soubannier V, Stifani S. NF-κB signalling in glioblastoma. Biomedicines. 2017;5(2):29. doi: 10.3390/biomedicines5020029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines5020029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan K, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013;26(6):701–707. doi: 10.1097/WCO.0000000000000032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000032</ArticleId>
            <ArticleId IdType="pmc">PMC4031658</ArticleId>
            <ArticleId IdType="pubmed">24152818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cahill KE, Morshed RA, Yamini B. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. Neuro-Oncology. 2015;18(3):329–339. doi: 10.1093/neuonc/nov265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov265</ArticleId>
            <ArticleId IdType="pmc">PMC4767244</ArticleId>
            <ArticleId IdType="pubmed">26534766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fallon KB, Havlioglu N, Hamilton LH, Cheng TP, Carroll SL. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neurooncol. 2004;66(3):273–284. doi: 10.1023/b:neon.0000014521.28294.84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/b:neon.0000014521.28294.84</ArticleId>
            <ArticleId IdType="pubmed">15015657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin WW, Ou GY, Lin JZ, Yi SJ, Yao WC, Pan HC, Zhao WJ. Neuregulin 1 enhances cell adhesion molecule L1 like expression levels and promotes malignancy in human glioma. Oncol Lett. 2020;20(1):326–336. doi: 10.3892/ol.2020.11548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2020.11548</ArticleId>
            <ArticleId IdType="pmc">PMC7285836</ArticleId>
            <ArticleId IdType="pubmed">32565959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao WJ, Schachner M. Neuregulin 1 enhances cell adhesion molecule l1 expression in human glioma cells and promotes their migration as a function of malignancy. J Neuropathol Exp Neurol. 2013;72(3):244–255. doi: 10.1097/NEN.0b013e3182863dc5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e3182863dc5</ArticleId>
            <ArticleId IdType="pubmed">23399902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritch PS, Carroll SL, Sontheimer H. Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia. 2005;51(3):217–228. doi: 10.1002/glia.20197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20197</ArticleId>
            <ArticleId IdType="pmc">PMC2548407</ArticleId>
            <ArticleId IdType="pubmed">15812817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Achenbach C, Weller M, Szabo E. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. J Neurochem. 2018;147(1):99–109. doi: 10.1111/jnc.14538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14538</ArticleId>
            <ArticleId IdType="pubmed">29953622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donaires FS, Godoy PR, Leandro GS, Puthier D, Sakamoto-Hojo ET. E2F transcription factors associated with up-regulated genes in glioblastoma. Cancer Biomark. 2017;18(2):199–208. doi: 10.3233/CBM-161628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/CBM-161628</ArticleId>
            <ArticleId IdType="pubmed">27983535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orozco-Morales M, Sánchez-García FJ, Golán-Cancela I, Hernández-Pedro N, Costoya JA, de la Cruz VP, Moreno-Jiménez S, Sotelo J, Pineda B. RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells. Cancer Cell Int. 2015;15:57. doi: 10.1186/s12935-015-0209-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-015-0209-x</ArticleId>
            <ArticleId IdType="pmc">PMC4491266</ArticleId>
            <ArticleId IdType="pubmed">26146488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip W, Shao W, Chiang YT, Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. Am J Physiol Endocrinol Metab. 2012;303(9):E1166–E1176. doi: 10.1152/ajpendo.00249.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00249.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3492858</ArticleId>
            <ArticleId IdType="pubmed">22967502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreira S, Polena E, Gordon V, Abdulla S, Mahendram S, Cao J, Blais A, Wood GA, Dvorkin-Gheva A, Doble BW. A single TCF transcription factor, regardless of its activation capacity, is sufficient for effective trilineage differentiation of ESCs. Cell Rep. 2017;20(10):2424–2438. doi: 10.1016/j.celrep.2017.08.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.08.043</ArticleId>
            <ArticleId IdType="pubmed">28877475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doumpas N, Lampart F, Robinson MD, et al.  TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. EMBO J. 2019;38(2):e98873. doi: 10.15252/embj.201798873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201798873</ArticleId>
            <ArticleId IdType="pmc">PMC6331726</ArticleId>
            <ArticleId IdType="pubmed">30425074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014;32(6):190–201. doi: 10.3109/08977194.2014.985787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08977194.2014.985787</ArticleId>
            <ArticleId IdType="pmc">PMC4693299</ArticleId>
            <ArticleId IdType="pubmed">25418012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ylivinkka I, Sihto H, Tynninen O, et al.  Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness. J Exp Clin Cancer Res. 2017;36:9. doi: 10.1186/s13046-016-0482-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0482-0</ArticleId>
            <ArticleId IdType="pmc">PMC5223529</ArticleId>
            <ArticleId IdType="pubmed">28069038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Ge R, Zhou J, et al.  Nuclear factor IX promotes glioblastoma development through transcriptional activation of Ezrin. Oncogenesis. 2020;9(4):39. doi: 10.1038/s41389-020-0223-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41389-020-0223-2</ArticleId>
            <ArticleId IdType="pmc">PMC7156762</ArticleId>
            <ArticleId IdType="pubmed">32291386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang W. The role of HOPX in normal tissues and tumor progression. Biosci Rep. 2020;40(1):BSR20191953. doi: 10.1042/BSR20191953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20191953</ArticleId>
            <ArticleId IdType="pmc">PMC6997107</ArticleId>
            <ArticleId IdType="pubmed">31934721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Toni A, Zbinden M, Epstein JA, Ruiz i Altaba A, Prochiantz A, Caillé I. Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP. Neural Dev. 2008;3:13. doi: 10.1186/1749-8104-3-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1749-8104-3-13</ArticleId>
            <ArticleId IdType="pmc">PMC2416439</ArticleId>
            <ArticleId IdType="pubmed">18507846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity [published correction appears in Curr Biol. 2007 Jan 23;17(2):192] Curr Biol. 2007;17(2):165–172. doi: 10.1016/j.cub.2006.11.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2006.11.033</ArticleId>
            <ArticleId IdType="pmc">PMC1855204</ArticleId>
            <ArticleId IdType="pubmed">17196391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lino MM, Merlo A, Boulay JL. Notch signaling in glioblastoma: a developmental drug target? BMC Med. 2010;8:72. doi: 10.1186/1741-7015-8-72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-8-72</ArticleId>
            <ArticleId IdType="pmc">PMC2996337</ArticleId>
            <ArticleId IdType="pubmed">21078177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazzoni R, Bentivegna A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel). 2019;11(3):292. doi: 10.3390/cancers11030292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11030292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiu MX, Liu YM, Kuang BH. The role of DLLs in cancer: a novel therapeutic target. Onco Targets Ther. 2020;13:3881–3901. doi: 10.2147/OTT.S244860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S244860</ArticleId>
            <ArticleId IdType="pmc">PMC7213894</ArticleId>
            <ArticleId IdType="pubmed">32440154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Hindy N, Keyvani K, Pagenstecher A, et al.  Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol. 2013;15(10):1366–1378. doi: 10.1093/neuonc/not071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not071</ArticleId>
            <ArticleId IdType="pmc">PMC3779034</ArticleId>
            <ArticleId IdType="pubmed">23787764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockhausen MT, Kristoffersen K, Poulsen HS. The functional role of Notch signaling in human gliomas. Neuro Oncol. 2010;12(2):199–211. doi: 10.1093/neuonc/nop022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nop022</ArticleId>
            <ArticleId IdType="pmc">PMC2940575</ArticleId>
            <ArticleId IdType="pubmed">20150387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J, Nakazato Y. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol. 2012;29(3):160–167. doi: 10.1007/s10014-012-0081-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10014-012-0081-5</ArticleId>
            <ArticleId IdType="pubmed">22350668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun. 2013;433(4):496–501. doi: 10.1016/j.bbrc.2013.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.03.021</ArticleId>
            <ArticleId IdType="pubmed">23524267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matini AH, Mofidi Naeini M, Haddad Kashani H, Vakili Z. Evaluation of Nestin and EGFR in patients with glioblastoma multiforme in a public hospital in Iran. Asian Pac J Cancer Prev. 2020;21(10):2889–2894. doi: 10.31557/APJCP.2020.21.10.2889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2020.21.10.2889</ArticleId>
            <ArticleId IdType="pmc">PMC7798165</ArticleId>
            <ArticleId IdType="pubmed">33112545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gersey Z, Osiason AD, Bloom L, Shah S, Thompson JW, Bregy A, Agarwal N, Komotar RJ. Therapeutic targeting of the notch pathway in glioblastoma multiforme. World Neurosurg. 2019;131:252–263.e2. doi: 10.1016/j.wneu.2019.07.180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2019.07.180</ArticleId>
            <ArticleId IdType="pubmed">31376551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget. 2016;7(27):41251–41264. doi: 10.18632/oncotarget.9275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9275</ArticleId>
            <ArticleId IdType="pmc">PMC5173056</ArticleId>
            <ArticleId IdType="pubmed">27183910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Liu Z, Jiang B, Peng R, Ma Z, Lu J. SOX9 overexpression promotes glioma metastasis via Wnt/β-catenin signaling. Cell Biochem Biophys. 2015;73(1):205–212. doi: 10.1007/s12013-015-0647-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12013-015-0647-z</ArticleId>
            <ArticleId IdType="pubmed">25716338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, Tu Y, Zhang Y. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29(5):3484–3490. doi: 10.1007/s12032-012-0267-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-012-0267-z</ArticleId>
            <ArticleId IdType="pubmed">22714060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Rocha AM, Sampron N, Alonso MM, Matheu A. Role of SOX family of transcription factors in central nervous system tumors. Am J Cancer Res. 2014;4(4):312–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4106650</ArticleId>
            <ArticleId IdType="pubmed">25057435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komada M. Sonic hedgehog signaling coordinates the proliferation and differentiation of neural stem/progenitor cells by regulating cell cycle kinetics during development of the neocortex. Congenit Anom (Kyoto). 2012;52(2):72–77. doi: 10.1111/j.1741-4520.2012.00368.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1741-4520.2012.00368.x</ArticleId>
            <ArticleId IdType="pubmed">22639991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carballo GB, Honorato JR, de Lopes GPF, Spohr TCLSE. A highlight on Sonic hedgehog pathway. Cell Commun Signal. 2018;16(1):11. doi: 10.1186/s12964-018-0220-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-018-0220-7</ArticleId>
            <ArticleId IdType="pmc">PMC5861627</ArticleId>
            <ArticleId IdType="pubmed">29558958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hung HC, Liu CC, Chuang JY, Su CL, Gean PW. Inhibition of sonic hedgehog signaling suppresses glioma stem-like cells likely through inducing autophagic cell death. Front Oncol. 2020;10:1233. doi: 10.3389/fonc.2020.01233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01233</ArticleId>
            <ArticleId IdType="pmc">PMC7393230</ArticleId>
            <ArticleId IdType="pubmed">32793494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariyath MPM, Shahi MH, Farheen S, Tayyab M, Khanam N, Ali A. Novel homeodomain transcription factor Nkx2.2 in the brain tumor development. Curr Cancer Drug Targets. 2020;20(5):335–340. doi: 10.2174/1568009618666180102111539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568009618666180102111539</ArticleId>
            <ArticleId IdType="pubmed">29295693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013;19(11):1518–1523. doi: 10.1038/nm.3328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3328</ArticleId>
            <ArticleId IdType="pmc">PMC3923315</ArticleId>
            <ArticleId IdType="pubmed">24076665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt MJ, Company C, Dramaretska Y, Barozzi I, Göhrig A, Kertalli S, Großmann M, Naumann H, Sanchez-Bailon MP, Hulsman D, Glass R, Squatrito M, Serresi M, Gargiulo G. Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing. Cancer Discov. 2021;11(3):754–777. doi: 10.1158/2159-8290.CD-20-0219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-20-0219</ArticleId>
            <ArticleId IdType="pmc">PMC7611210</ArticleId>
            <ArticleId IdType="pubmed">33361384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajetto A, Thellung S, Dellacasagrande I, Pagano A, Barbieri F, Florio T. Cross talk between mesenchymal and glioblastoma stem cells: communication beyond controversies. Stem Cells Transl Med. 2020;9(11):1310–1330. doi: 10.1002/sctm.20-0161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sctm.20-0161</ArticleId>
            <ArticleId IdType="pmc">PMC7581451</ArticleId>
            <ArticleId IdType="pubmed">32543030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes Dev. 2017;31(12):1212–1227. doi: 10.1101/gad.300079.117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.300079.117</ArticleId>
            <ArticleId IdType="pmc">PMC5558924</ArticleId>
            <ArticleId IdType="pubmed">28724615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guichet PO, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, Scamps F, Ripoll C, Vacher S, Taviaux S, Chevassus H, Duffau H, Mallet J, Susini A, Joubert D, Bauchet L, Hugnot JP. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013;61(2):225–239. doi: 10.1002/glia.22429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.22429</ArticleId>
            <ArticleId IdType="pubmed">23047160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Z, Zang T, Liu ML, Wang LL, Niu W, Zhang CL. Reprogramming the fate of human glioma cells to impede brain tumor development. Cell Death Dis. 2014;5(10):e1463. doi: 10.1038/cddis.2014.425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.425</ArticleId>
            <ArticleId IdType="pmc">PMC4649522</ArticleId>
            <ArticleId IdType="pubmed">25321470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Pei Z, Hossain A, Bai Y, Chen G. Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion. Cancer Biol Med. 2021. 10.20892/j.issn.2095-3941.2020.0499 Epub ahead of print. PMID: 33755378.</Citation>
        </Reference>
        <Reference>
          <Citation>Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O'Rourke DM. SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol. 2017;135(3):487–496. doi: 10.1007/s11060-017-2610-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2610-x</ArticleId>
            <ArticleId IdType="pubmed">28852935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Xing H, Kim TM, et al.  Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells. 2012;30(7):1313–1326. doi: 10.1002/stem.1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1120</ArticleId>
            <ArticleId IdType="pmc">PMC3963835</ArticleId>
            <ArticleId IdType="pubmed">22553175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Euskirchen P, Skaftnesmo KO, Huszthy PC, Brekkå N, Bjerkvig R, Jacobs AH, Miletic H. NUMB does not impair growth and differentiation status of experimental gliomas. Exp Cell Res. 2011;317(20):2864–2873. doi: 10.1016/j.yexcr.2011.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2011.09.002</ArticleId>
            <ArticleId IdType="pubmed">21939656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung HH, Lee CT, Hu JM, Chou YC, Lin YW, Shih YL. NKX6.1 represses tumorigenesis, metastasis, and chemoresistance in colorectal cancer. Int J Mol Sci. 2020;21(14):5106. doi: 10.3390/ijms21145106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21145106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li HJ, Yu PN, Huang KY, Su HY, Hsiao TH, Chang CP, Yu MH, Lin YW. NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene. 2016;35(17):2266–2278. doi: 10.1038/onc.2015.289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.289</ArticleId>
            <ArticleId IdType="pmc">PMC4855079</ArticleId>
            <ArticleId IdType="pubmed">26257059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park NI, Guilhamon P, Desai K, RF MA, Langille E, O'Connor M, Lan X, Whetstone H, Coutinho FJ, Vanner RJ, Ling E, Prinos P, Lee L, Selvadurai H, Atwal G, Kushida M, Clarke ID, Voisin V, Cusimano MD, Bernstein M, Das S, Bader G, Arrowsmith CH, Angers S, Huang X, Lupien M, Dirks PB. ASCL1 reorganizes chromatin to direct neuronal fate and suppress tumorigenicity of glioblastoma stem cells. Cell Stem Cell. 2017;21(2):209–224.e7. doi: 10.1016/j.stem.2017.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2017.06.004</ArticleId>
            <ArticleId IdType="pubmed">28712938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao D. Emerging roles of the EBF family of transcription factors in tumor suppression. Mol Cancer Res. 2009;7(12):1893–1901. doi: 10.1158/1541-7786.MCR-09-0229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-09-0229</ArticleId>
            <ArticleId IdType="pmc">PMC5545892</ArticleId>
            <ArticleId IdType="pubmed">19996307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melhuish TA, Kowalczyk I, Manukyan A, Zhang Y, Shah A, Abounader R, Wotton D. Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech. 2018;1861(11):983–995. doi: 10.1016/j.bbagrm.2018.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagrm.2018.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC6203443</ArticleId>
            <ArticleId IdType="pubmed">30312684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawn S, Krishna N, Pisklakova A, et al.  Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem. 2015;290(6):3814–3824. doi: 10.1074/jbc.M114.599373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.599373</ArticleId>
            <ArticleId IdType="pmc">PMC4319045</ArticleId>
            <ArticleId IdType="pubmed">25538243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, Wu J, Xu X, Fu L, Li Y, Yang J, Zhang W, Bai R, Yi F, Suzuki K, Gao H, Esteban CR, Zhang C, Izpisua Belmonte JC, Chen Z, Wang X, Jiang T, Qu J, Tang F, Liu GH. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun. 2015;6:10068. doi: 10.1038/ncomms10068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10068</ArticleId>
            <ArticleId IdType="pmc">PMC4686761</ArticleId>
            <ArticleId IdType="pubmed">26632666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu YT, Li BF, Zhang PJ, et al.  Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines via regulating Shh-Gli1 signaling. World J Gastroenterol. 2019;25(8):923–940. doi: 10.3748/wjg.v25.i8.923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v25.i8.923</ArticleId>
            <ArticleId IdType="pmc">PMC6397724</ArticleId>
            <ArticleId IdType="pubmed">30833799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sangpairoj K, Vivithanaporn P, Apisawetakan S, Chongthammakun S, Sobhon P, Chaithirayanon K. RUNX1 regulates migration, invasion, and angiogenesis via p38 MAPK pathway in human glioblastoma. Cell Mol Neurobiol. 2017;37(7):1243–1255. doi: 10.1007/s10571-016-0456-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10571-016-0456-y</ArticleId>
            <ArticleId IdType="pubmed">28012022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada D, Fujikawa K, Kawabe K, Furuta T, Nakada M, Takarada T. RUNX2 promotes malignant progression in glioma. Neurochem Res. 2018;43(11):2047–2054. doi: 10.1007/s11064-018-2626-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-018-2626-4</ArticleId>
            <ArticleId IdType="pubmed">30203400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest. 2016;96(2):137–150. doi: 10.1038/labinvest.2015.140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2015.140</ArticleId>
            <ArticleId IdType="pubmed">26641068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shevchenko V, Arnotskaya N, Korneyko M, Zaytsev S, Khotimchenko Y, Sharma H, Bryukhovetskiy I. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma. Oncol Rep. 2019;41(5):3080–3088. doi: 10.3892/or.2019.7043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7043</ArticleId>
            <ArticleId IdType="pubmed">30864699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt pathway to defining biology of glioblastoma. Neuromolecular Med. 2018;20(4):437–451. doi: 10.1007/s12017-018-8514-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-018-8514-x</ArticleId>
            <ArticleId IdType="pubmed">30259273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotliarova S, Pastorino S, Kovell LC, et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008;68(16):6643–6651. doi: 10.1158/0008-5472.CAN-08-0850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-0850</ArticleId>
            <ArticleId IdType="pmc">PMC2585745</ArticleId>
            <ArticleId IdType="pubmed">18701488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proctor CJ, Gray DA. GSK3 and p53 - is there a link in Alzheimer’s disease? Mol Neurodegener. 2010;5:7. doi: 10.1186/1750-1326-5-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1326-5-7</ArticleId>
            <ArticleId IdType="pmc">PMC2831894</ArticleId>
            <ArticleId IdType="pubmed">20181016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WY, Snider WD. Functions of GSK-3 signaling in development of the nervous system. Front Mol Neurosci. 2011;4:44. doi: 10.3389/fnmol.2011.00044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2011.00044</ArticleId>
            <ArticleId IdType="pmc">PMC3221276</ArticleId>
            <ArticleId IdType="pubmed">22125510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YT, Hur EM, Snider WD, Zhou FQ. Role of GSK3 signaling in neuronal morphogenesis. Front Mol Neurosci. 2011;4:48. doi: 10.3389/fnmol.2011.00048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2011.00048</ArticleId>
            <ArticleId IdType="pmc">PMC3222852</ArticleId>
            <ArticleId IdType="pubmed">22131966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11(8):539–551. doi: 10.1038/nrn2870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2870</ArticleId>
            <ArticleId IdType="pmc">PMC3533361</ArticleId>
            <ArticleId IdType="pubmed">20648061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majewska E, Szeliga M. AKT/GSK3β signaling in glioblastoma. Neurochem Res. 2017;42(3):918–924. doi: 10.1007/s11064-016-2044-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-016-2044-4</ArticleId>
            <ArticleId IdType="pmc">PMC5357492</ArticleId>
            <ArticleId IdType="pubmed">27568206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domoto T, Uehara M, Bolidong D, Minamoto T. Glycogen synthase kinase 3β in cancer biology and treatment. Cells. 2020;9(6):1388. doi: 10.3390/cells9061388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9061388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenci T, Martini M, Montano N, D'Alessandris QG, Falchetti ML, Annibali D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. Am J Clin Pathol. 2012;138(3):390–396. doi: 10.1309/AJCPRXHNJQLO09QA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPRXHNJQLO09QA</ArticleId>
            <ArticleId IdType="pubmed">22912356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins DM, Wang R, Milligan B, Schroeder M, Carlson B, Pokorny J, Cheshier SH, Meyer FB, Weissman IL, Sarkaria JN, Henley JR. Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget. 2013;4(5):792–801. doi: 10.18632/oncotarget.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1059</ArticleId>
            <ArticleId IdType="pmc">PMC3742839</ArticleId>
            <ArticleId IdType="pubmed">23801022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray SK. The transcription regulator Krüppel-like factor 4 and its dual roles of oncogene in glioblastoma and tumor suppressor in neuroblastoma. For Immunopathol Dis Therap. 2016;7(1-2):127–139. doi: 10.1615/ForumImmunDisTher.2016017227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/ForumImmunDisTher.2016017227</ArticleId>
            <ArticleId IdType="pmc">PMC5423539</ArticleId>
            <ArticleId IdType="pubmed">28497005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson E, Zhai Q, Zeng ZJ, Yoshida T, Funa K. Nuclear receptor TLX inhibits TGF-β signaling in glioblastoma. Exp Cell Res. 2016;343(2):118–125. doi: 10.1016/j.yexcr.2016.03.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2016.03.028</ArticleId>
            <ArticleId IdType="pubmed">27048878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Niu W, Qin S, Downes M, Burns DK, Zhang CL. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche. Mol Cell Biol. 2012;32(23):4811–4820. doi: 10.1128/MCB.01122-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01122-12</ArticleId>
            <ArticleId IdType="pmc">PMC3497606</ArticleId>
            <ArticleId IdType="pubmed">23028043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodorou E, Dalembert G, Heffelfinger C, et al.  A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. Genes Dev. 2009;23(5):575–588. doi: 10.1101/gad.1772509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1772509</ArticleId>
            <ArticleId IdType="pmc">PMC2658525</ArticleId>
            <ArticleId IdType="pubmed">19270158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tantin D. Oct transcription factors in development and stem cells: insights and mechanisms. Development. 2013;140(14):2857–2866. doi: 10.1242/dev.095927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.095927</ArticleId>
            <ArticleId IdType="pmc">PMC3699277</ArticleId>
            <ArticleId IdType="pubmed">23821033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira AI, Anjo SI, Vieira de Castro J, Serra SC, Salgado AJ, Manadas B, Costa BM. Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells. Cell Commun Signal. 2017;15(1):37. doi: 10.1186/s12964-017-0194-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-017-0194-x</ArticleId>
            <ArticleId IdType="pmc">PMC5625790</ArticleId>
            <ArticleId IdType="pubmed">28969644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucheryavykh LY, Rolón-Reyes K, Kucheryavykh YV, et al.  Glioblastoma development in mouse brain: general reduction of OCTs and mislocalization of OCT3 transporter and subsequent uptake of ASP+ substrate to the nuclei. J Neurosci Neuroeng. 2014;3(1):3–9. doi: 10.1166/jnsne.2014.1091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1166/jnsne.2014.1091</ArticleId>
            <ArticleId IdType="pmc">PMC4143131</ArticleId>
            <ArticleId IdType="pubmed">25165637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Qiu J, Zhang Z, et al.  SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study. Cell Biosci. 2021;11:23. doi: 10.1186/s13578-021-00539-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-021-00539-y</ArticleId>
            <ArticleId IdType="pmc">PMC7821488</ArticleId>
            <ArticleId IdType="pubmed">33482915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, Miyazono K. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem. 2011;286(48):41434–41441. doi: 10.1074/jbc.M111.300863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.300863</ArticleId>
            <ArticleId IdType="pmc">PMC3308855</ArticleId>
            <ArticleId IdType="pubmed">21987575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells. 2010;28(6):1019–1029. doi: 10.1002/stem.429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.429</ArticleId>
            <ArticleId IdType="pmc">PMC5532884</ArticleId>
            <ArticleId IdType="pubmed">20506127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu YY, Zheng MH, Cheng G, et al.  Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011;11:82. doi: 10.1186/1471-2407-11-82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-11-82</ArticleId>
            <ArticleId IdType="pmc">PMC3052197</ArticleId>
            <ArticleId IdType="pubmed">21342503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi L, Zhou X, Li T, et al.  Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 2019;38:339. doi: 10.1186/s13046-019-1319-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1319-4</ArticleId>
            <ArticleId IdType="pmc">PMC6683584</ArticleId>
            <ArticleId IdType="pubmed">31382985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 2018;23:12. doi: 10.1186/s11658-018-0078-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-018-0078-0</ArticleId>
            <ArticleId IdType="pmc">PMC5863838</ArticleId>
            <ArticleId IdType="pubmed">29588647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandru O, Horescu C, Sevastre AS, et al.  Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Contemp Oncol (Pozn). 2020;24(1):55–66. doi: 10.5114/wo.2020.94726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2020.94726</ArticleId>
            <ArticleId IdType="pmc">PMC7265959</ArticleId>
            <ArticleId IdType="pubmed">32514239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019;25(1):176–187. doi: 10.1038/s41591-018-0263-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0263-8</ArticleId>
            <ArticleId IdType="pmc">PMC6857804</ArticleId>
            <ArticleId IdType="pubmed">30531922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DY, Yeh TH, Emnett RJ, White CR, Gutmann DH. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev. 2010;24(20):2317–2329. doi: 10.1101/gad.1957110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1957110</ArticleId>
            <ArticleId IdType="pmc">PMC2956210</ArticleId>
            <ArticleId IdType="pubmed">20876733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YH, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes Dev. 2015;29(16):1677–1682. doi: 10.1101/gad.261677.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.261677.115</ArticleId>
            <ArticleId IdType="pmc">PMC4561477</ArticleId>
            <ArticleId IdType="pubmed">26272820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012;150(4):816–830. doi: 10.1016/j.cell.2012.06.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.034</ArticleId>
            <ArticleId IdType="pmc">PMC3427010</ArticleId>
            <ArticleId IdType="pubmed">22901811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ, Phillips JJ, Weiss WA, Resnick AC, Gosline S, Banerjee J, Guinney J, Gnekow A, Kandels D, Foreman NK, Korshunov A, Ryzhova M, Massimi L, Gururangan S, Kieran MW, Wang Z, Fouladi M, Sato M, Øra I, Holm S, Markham SJ, Beck P, Jäger N, Wittmann A, Sommerkamp AC, Sahm F, Pfister SM, Gutmann DH. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1) Acta Neuropathol. 2021;141(4):605–617. doi: 10.1007/s00401-021-02276-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-021-02276-5</ArticleId>
            <ArticleId IdType="pubmed">33585982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jecrois ES, Zheng W, Bornhorst M, Li Y, Treisman DM, Muguyo D, Huynh S, Andrew SF, Wang Y, Jiang J, Pierce BR, Mao H, Krause MK, Friend A, Nadal-Nicolas F, Stasheff SF, Li W, Zong H, Packer RJ, Zhu Y. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. Dev Cell. 2021;56(20):2871–2885.e6. doi: 10.1016/j.devcel.2021.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2021.08.004</ArticleId>
            <ArticleId IdType="pubmed">34428430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, Suzuki Y, Mashiyama S, Uenohara H, Watanabe M, Kumabe T, Tominaga T. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol. 2018;35(1):10–18. doi: 10.1007/s10014-017-0302-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10014-017-0302-z</ArticleId>
            <ArticleId IdType="pubmed">29138945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aranha MM, Solá S, Low WC, Steer CJ, Rodrigues CM. Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J Cell Biochem. 2009;107(4):748–758. doi: 10.1002/jcb.22172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.22172</ArticleId>
            <ArticleId IdType="pubmed">19415678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Rielland M, Yalcin S, Ghaffari S. Regulation and function of FoxO transcription factors in normal and cancer stem cells: what have we learned? Curr Drug Targets. 2011;12(9):1267–1283. doi: 10.2174/138945011796150325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138945011796150325</ArticleId>
            <ArticleId IdType="pubmed">21443463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:925350. doi: 10.1155/2014/925350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/925350</ArticleId>
            <ArticleId IdType="pmc">PMC4016844</ArticleId>
            <ArticleId IdType="pubmed">24864265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Z, Ren L, Wu D, Yang X, Zhou Z, Nie Q, Jiang G, Xue S, Weng W, Qiu Y, Lin Y. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. Int J Cancer. 2017;140(12):2792–2804. doi: 10.1002/ijc.30690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30690</ArticleId>
            <ArticleId IdType="pubmed">28295288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau CJ, Koty Z, Nalbantoglu J. Differential response of glioma cells to FOXO1-directed therapy. Cancer Res. 2009;69(13):5433–5440. doi: 10.1158/0008-5472.CAN-08-4540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-4540</ArticleId>
            <ArticleId IdType="pubmed">19549905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells. 2011;29(9):1327–1337. doi: 10.1002/stem.696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.696</ArticleId>
            <ArticleId IdType="pubmed">21793107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Wang J, Jin T, Zhou Y, Chen Q. FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma. Biochem Biophys Res Commun. 2018;504(1):46–53. doi: 10.1016/j.bbrc.2018.08.118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.08.118</ArticleId>
            <ArticleId IdType="pubmed">30172378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong Y, Zhang Y, Xiong S, Williams-Villalobo AE. A glance of p53 functions in brain development, neural stem cells, and brain cancer. Biology (Basel). 2020;9(9):285. doi: 10.3390/biology9090285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biology9090285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi R, Giannini C, Sarkaria JN, et al.  p53 isoform profiling in glioblastoma and injured brain. Oncogene. 2013;32(26):3165–3174. doi: 10.1038/onc.2012.322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.322</ArticleId>
            <ArticleId IdType="pmc">PMC3904233</ArticleId>
            <ArticleId IdType="pubmed">22824800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin Navarro A, Pronk RJ, van der Geest AT, Oliynyk G, Nordgren A, Arsenian-Henriksson M, Falk A, Wilhelm M. p53 controls genomic stability and temporal differentiation of human neural stem cells and affects neural organization in human brain organoids. Cell Death Dis. 2020;11(1):52. doi: 10.1038/s41419-019-2208-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2208-7</ArticleId>
            <ArticleId IdType="pmc">PMC6978389</ArticleId>
            <ArticleId IdType="pubmed">31974372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Dube C, Gibert M, Jr, et al.  The p53 pathway in glioblastoma. Cancers (Basel) 2018;10(9):297. doi: 10.3390/cancers10090297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10090297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagpal J, Jamoona A, Gulati ND, Mohan A, Braun A, Murali R, Jhanwar-Uniyal M. Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res. 2006;26(6C):4633–4639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17214319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30–39. doi: 10.1016/j.ebiom.2016.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2016.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC4919535</ArticleId>
            <ArticleId IdType="pubmed">27428416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol. 1997;56(2):180–185. doi: 10.1097/00005072-199702000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-199702000-00009</ArticleId>
            <ArticleId IdType="pubmed">9034372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir. 2003;64(1):30–36. doi: 10.1055/s-2003-37149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2003-37149</ArticleId>
            <ArticleId IdType="pubmed">12582944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson KL, Slack RS. The Rb pathway in neurogenesis. Neuroreport. 2001;12(9):A55–A62. doi: 10.1097/00001756-200107030-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-200107030-00001</ArticleId>
            <ArticleId IdType="pubmed">11435948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res. 2005;94:1–27. doi: 10.1016/S0065-230X(05)94001-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-230X(05)94001-3</ArticleId>
            <ArticleId IdType="pubmed">16095998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson KL, Vanderluit JL, Hébert JM, et al.  Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development. EMBO J. 2002;21(13):3337–3346. doi: 10.1093/emboj/cdf338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdf338</ArticleId>
            <ArticleId IdType="pmc">PMC126087</ArticleId>
            <ArticleId IdType="pubmed">12093735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T, Goldstein M, Kim AH, Huang J. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncol Adv. 2020;2(1):vdaa126. doi: 10.1093/noajnl/vdaa126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/noajnl/vdaa126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. J Neurooncol. 2016;127(3):483–492. doi: 10.1007/s11060-016-2066-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-016-2066-4</ArticleId>
            <ArticleId IdType="pmc">PMC4835517</ArticleId>
            <ArticleId IdType="pubmed">26839018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012;14(7):870–881. doi: 10.1093/neuonc/nos114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos114</ArticleId>
            <ArticleId IdType="pmc">PMC3379801</ArticleId>
            <ArticleId IdType="pubmed">22711607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karpel-Massler G, Nguyen TTT, Shang E, Siegelin MD. Novel IDH1-targeted glioma therapies. CNS Drugs. 2019;33(12):1155–1166. doi: 10.1007/s40263-019-00684-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-019-00684-6</ArticleId>
            <ArticleId IdType="pmc">PMC7027940</ArticleId>
            <ArticleId IdType="pubmed">31768950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18(9):2490–2501. doi: 10.1158/1078-0432.CCR-11-2977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2977</ArticleId>
            <ArticleId IdType="pubmed">22415316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–1589. doi: 10.1038/s41416-020-0814-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-0814-x</ArticleId>
            <ArticleId IdType="pmc">PMC7250901</ArticleId>
            <ArticleId IdType="pubmed">32291392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–1153. doi: 10.2353/ajpath.2009.080958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2009.080958</ArticleId>
            <ArticleId IdType="pmc">PMC2671348</ArticleId>
            <ArticleId IdType="pubmed">19246647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17(1):45–52. doi: 10.1093/neuonc/nou158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou158</ArticleId>
            <ArticleId IdType="pmc">PMC4483052</ArticleId>
            <ArticleId IdType="pubmed">25140036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013;126(6):931–937. doi: 10.1007/s00401-013-1163-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-013-1163-0</ArticleId>
            <ArticleId IdType="pubmed">23955565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M. TERT promoter alterations in glioblastoma: a systematic review. Cancers (Basel). 2021;13(5):1147. doi: 10.3390/cancers13051147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051147</ArticleId>
            <ArticleId IdType="pmc">PMC7962450</ArticleId>
            <ArticleId IdType="pubmed">33800183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumgarten P, Harter PN, Tönjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kögel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zörnig M, Mittelbronn M. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2):205–216. doi: 10.1111/nan.12088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12088</ArticleId>
            <ArticleId IdType="pubmed">24117486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–722. doi: 10.18632/oncotarget.588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.588</ArticleId>
            <ArticleId IdType="pmc">PMC3443254</ArticleId>
            <ArticleId IdType="pubmed">22869205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297. doi: 10.1007/s13311-017-0519-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-017-0519-x</ArticleId>
            <ArticleId IdType="pmc">PMC5398991</ArticleId>
            <ArticleId IdType="pubmed">28281173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683–2710. doi: 10.1101/gad.1596707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1596707</ArticleId>
            <ArticleId IdType="pubmed">17974913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–122. doi: 10.1158/2326-6066.CIR-13-0028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0028</ArticleId>
            <ArticleId IdType="pmc">PMC3881271</ArticleId>
            <ArticleId IdType="pubmed">24409449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi: 10.1016/j.ccr.2009.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.12.020</ArticleId>
            <ArticleId IdType="pmc">PMC2818769</ArticleId>
            <ArticleId IdType="pubmed">20129251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci. 2019;20(11):2746. doi: 10.3390/ijms20112746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20112746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33(25):2735–2744. doi: 10.1200/JCO.2015.61.5005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.61.5005</ArticleId>
            <ArticleId IdType="pmc">PMC5015426</ArticleId>
            <ArticleId IdType="pubmed">26124478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro Oncol. 2019;21(1):59–70. doi: 10.1093/neuonc/noy120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy120</ArticleId>
            <ArticleId IdType="pmc">PMC6303485</ArticleId>
            <ArticleId IdType="pubmed">30053126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2012;50(4):301–321. doi: 10.5114/fn.2012.32361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/fn.2012.32361</ArticleId>
            <ArticleId IdType="pubmed">23319187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steponaitis G, Tamasauskas A. Mesenchymal and proneural subtypes of glioblastoma disclose branching based on GSC associated signature. Int J Mol Sci. 2021;22(9):4964. doi: 10.3390/ijms22094964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22094964</ArticleId>
            <ArticleId IdType="pmc">PMC8124327</ArticleId>
            <ArticleId IdType="pubmed">34066996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behnan J, Finocchiaro G, Hanna G. The landscape of the mesenchymal signature in brain tumours. Brain. 2019;142(4):847–866. doi: 10.1093/brain/awz044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz044</ArticleId>
            <ArticleId IdType="pmc">PMC6485274</ArticleId>
            <ArticleId IdType="pubmed">30946477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, Sönmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B. Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition. Cell Rep. 2016;17(11):2994–3009. doi: 10.1016/j.celrep.2016.11.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.11.056</ArticleId>
            <ArticleId IdType="pubmed">27974212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inda MM, Bonavia R, Seoane J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel) 2014;6(1):226–239. doi: 10.3390/cancers6010226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6010226</ArticleId>
            <ArticleId IdType="pmc">PMC3980595</ArticleId>
            <ArticleId IdType="pubmed">24473088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55. doi: 10.3389/fonc.2015.00055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2015.00055</ArticleId>
            <ArticleId IdType="pmc">PMC4347445</ArticleId>
            <ArticleId IdType="pubmed">25785247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers (Basel). 2021;13(4):761. doi: 10.3390/cancers13040761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13040761</ArticleId>
            <ArticleId IdType="pmc">PMC7918815</ArticleId>
            <ArticleId IdType="pubmed">33673104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White CW, 3rd, Fan X, Maynard JC, Wheatley EG, Bieri G, Couthouis J, Burlingame AL, Villeda SA. Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation. Proc Natl Acad Sci U S A. 2020;117(36):22214–22224. doi: 10.1073/pnas.2007439117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2007439117</ArticleId>
            <ArticleId IdType="pmc">PMC7486730</ArticleId>
            <ArticleId IdType="pubmed">32848054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, Kline CN, Banerjee A, Reddy A, Oberheim Bush NA, Chang S, Braunstein S, Chang EF, Raffel C, Gupta N, Sun PP, Kim JYH, Moes G, Alva E, Li R, Bruggers CS, Alashari M, Wetmore C, Garg S, Dishop M, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Berger MS, Costello JF, Perry A, Solomon DA. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. Acta Neuropathol. 2020;139(5):953–957. doi: 10.1007/s00401-020-02144-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-020-02144-8</ArticleId>
            <ArticleId IdType="pmc">PMC7183424</ArticleId>
            <ArticleId IdType="pubmed">32157385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr BA, Clay MR, Pinto EM, Kesserwan C. An update on the central nervous system manifestations of Li-Fraumeni syndrome. Acta Neuropathol. 2020;139(4):669–687. doi: 10.1007/s00401-019-02055-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-019-02055-3</ArticleId>
            <ArticleId IdType="pubmed">31468188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9(4):535–539. doi: 10.1586/ern.09.4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/ern.09.4</ArticleId>
            <ArticleId IdType="pubmed">19344304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolillo M, Comincini S, Schinelli S. In vitro glioblastoma models: a journey into the third dimension. Cancers (Basel). 2021;13(10):2449. doi: 10.3390/cancers13102449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13102449</ArticleId>
            <ArticleId IdType="pmc">PMC8157833</ArticleId>
            <ArticleId IdType="pubmed">34070023</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
